var title_f27_21_27984="Common iliac artery aneurysm without distal landing zone";
var content_f27_21_27984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Common iliac artery aneurysm without distal landing zone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An isolated common iliac artery aneurysm without a distal landing zone can be managed with coil embolization of the internal ilac artery and endograft placement to exclude the aneurysm with extension into the external iliac artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27984=[""].join("\n");
var outline_f27_21_27984=null;
var title_f27_21_27985="2D TTE Suprasternal view right pulmonary artery";
var content_f27_21_27985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the suprasternal notch view showing the right pulmonary artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 180px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Imaging the transverse aortic arch (TAo) from the suprasternal notch should be a standard part of every echocardiographic examination; the right pulmonary artery (RPA) can be viewed and when compared to the diameter of the transverse aortic arch, provides valuable information about the differential diagnosis of right ventricular enlargement. In panel A, the patient had a small ventricular septal defect and borderline normal right ventricular size on echocardiography; the RPA is smaller than the TAo, indicating a very small left-to-right shunt. In panel B, the patient had an Ebstein's anomaly of the tricuspid valve, the large right atrium is associated with a smaller than normal RPA, confirming the reduced pulmonary flow resulting from decreased functional volume of the right ventricle, tricuspid regurgitation, and right-to-left shunt across the atrial septum. In panel C, the patient had an atrial septal defect; the RPA is considerably enlarged, confirming that the ASD is likely to be associated with a large left-to-right shunt.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27985=[""].join("\n");
var outline_f27_21_27985=null;
var title_f27_21_27986="Patient information: Behets disease (The Basics)";
var content_f27_21_27986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86918\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/43/37554\">",
"         Patient information: Medicine brand and generic names (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/57/37778\">",
"         Patient information: Steroid medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/13/26833\">",
"         Patient information: Uveitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/49/12051\">",
"         Patient information: Vasculitis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/40/27266\">",
"         Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/22/44389\">",
"         Patient information: Vasculitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Beh&ccedil;et&rsquo;s disease (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H865081112\">",
"      <span class=\"h1\">",
"       What is Beh&ccedil;et&rsquo;s disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Beh&ccedil;et&rsquo;s disease is a type of vasculitis, which is a general term that means inflammation of the blood vessels. Inflammation can make blood vessel walls thick, weak, narrow, or scarred. In Beh&ccedil;et&rsquo;s disease, these changes can happen in blood vessels all over the body. This can lead to different types of symptoms.",
"     </p>",
"     <p>",
"      Doctors don&rsquo;t know what causes Beh&ccedil;et&rsquo;s disease. It happens most often in adults age 20 to 40.",
"     </p>",
"     <p>",
"      Beh&ccedil;et&rsquo;s disease is a lifelong disease. Symptoms can come and go over time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865081127\">",
"      <span class=\"h1\">",
"       What are the symptoms of Beh&ccedil;et&rsquo;s disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Open sores (called &ldquo;ulcers&rdquo;) in the mouth &ndash; These sores can be very painful. They usually go away on their own, but then often come back later on.",
"       </li>",
"       <li>",
"        Open sores on the genitals &ndash; These sores can be very painful. They usually happen on the scrotum (the skin sac between the legs) in men or on the vulva (the area around the vagina) in women.",
"       </li>",
"       <li>",
"        Eye inflammation (called &ldquo;uveitis&rdquo;) &ndash; This can cause eye redness or pain, or blurred vision. If the eye inflammation isn&rsquo;t treated, it can lead to blindness.",
"       </li>",
"       <li>",
"        Arthritis, which is joint pain and swelling &ndash; This commonly affects the knees, ankles, or wrists.",
"       </li>",
"       <li>",
"        Skin symptoms &ndash; These can include bumps, rashes, or acne-like symptoms.",
"       </li>",
"       <li>",
"        Digestive symptoms &ndash; These happen when ulcers form in the digestive tract (",
"        <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"         figure 1",
"        </a>",
"        ). Symptoms can include lack of appetite, nausea, belly pain, or diarrhea.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with Beh&ccedil;et&rsquo;s disease can have other symptoms, too. These can affect the brain, kidneys, heart, lungs, or other parts of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865081165\">",
"      <span class=\"h1\">",
"       Is there a test for Beh&ccedil;et&rsquo;s disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no test that can tell for sure whether you have Beh&ccedil;et&rsquo;s disease. To figure out whether you have the disease, your doctor or nurse will ask about all of your symptoms and do an exam. He or she might also order blood tests to make sure your symptoms are not caused by another condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865081180\">",
"      <span class=\"h1\">",
"       How is Beh&ccedil;et&rsquo;s disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no cure for Beh&ccedil;et&rsquo;s disease. But medicines can help ease and control your symptoms. They can also help prevent long-term problems from the disease. The medicines that are right for you will depend on your symptoms and how severe your disease is.",
"     </p>",
"     <p>",
"      In general, doctors use the following medicines to treat Beh&ccedil;et&rsquo;s disease:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Steroid medicines, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"         prednisone",
"        </a>",
"        &ndash; These medicines reduce and control inflammation. Because steroid medicines can cause serious side effects, doctors try to give them for as short a time as possible. Steroid medicines are not the same as the steroids athletes take to build muscle.",
"       </li>",
"       <li>",
"        A medicine called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?39/40/40580?source=see_link\">",
"         colchicine",
"        </a>",
"        , which helps reduce pain and swelling",
"       </li>",
"       <li>",
"        Medicines that calm down or &ldquo;turn off&rdquo; the body&rsquo;s immune (infection-fighting) system",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other treatment depends on the part of the body affected. For example, eye inflammation is also treated with eye drops or other medicines that go in the eye.",
"     </p>",
"     <p>",
"      People with certain blood vessel problems might need treatment other than medicines. For example, if a blood vessel wall gets too thin and bulges out, it might need to be fixed with surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865081195\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor or nurse. Some medicines for Beh&ccedil;et&rsquo;s disease are not safe to take if you are pregnant. You might need to get your symptoms under control or switch medicines before you try to get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865081210\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will need regular exams and tests to check for the problems Beh&ccedil;et&rsquo;s disease can cause. It is important to take your medicines exactly as prescribed and tell your doctor or nurse if you have any side effects. The right treatment can help you control your symptoms and stay as healthy as possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865081225\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/49/12051?source=see_link\">",
"       Patient information: Vasculitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=see_link\">",
"       Patient information: Steroid medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=see_link\">",
"       Patient information: Medicine brand and generic names (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/13/26833?source=see_link\">",
"       Patient information: Uveitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"       Patient information: Vasculitis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/21/27986?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86918 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27986=[""].join("\n");
var outline_f27_21_27986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865081112\">",
"      What is Beh&ccedil;et&rsquo;s disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865081127\">",
"      What are the symptoms of Beh&ccedil;et&rsquo;s disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865081165\">",
"      Is there a test for Beh&ccedil;et&rsquo;s disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865081180\">",
"      How is Beh&ccedil;et&rsquo;s disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865081195\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865081210\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865081225\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86918\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=related_link\">",
"      Patient information: Medicine brand and generic names (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=related_link\">",
"      Patient information: Steroid medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/13/26833?source=related_link\">",
"      Patient information: Uveitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/49/12051?source=related_link\">",
"      Patient information: Vasculitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_21_27987="Candida glabrata";
var content_f27_21_27987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candida glabrata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Candida glabrata grows as a small, elliptical, budding, unicellular yeast. Buds rarely adhere to one another in rudimentary chains, but filamentous growth does not occur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wiley Schell, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27987=[""].join("\n");
var outline_f27_21_27987=null;
var title_f27_21_27988="RSV in neutropenia PA";
var content_f27_21_27988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    RSV infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest x-ray shows interstitial infiltrates in a peribronchovascular distribution in a neutropenic patient with malignant melanoma. The etiology was proven to be respiratory syncytial virus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jay Fishman, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27988=[""].join("\n");
var outline_f27_21_27988=null;
var title_f27_21_27989="Pasireotide: Drug information";
var content_f27_21_27989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pasireotide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/20/41285?source=see_link\">",
"    see \"Pasireotide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16355589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Signifor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15826667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Somatostatin Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16052571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cushing&rsquo;s disease:",
"     </b>",
"     SubQ: Initial: 0.6 mg or 0.9 mg twice daily; titrate based on response and tolerability; maximum urinary free cortisol reductions are usually observed by 2 months of treatment. Recommended dosage range: 0.3-0.9 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     If adverse reactions occur, temporarily decrease dose by 0.3 mg increments.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16052572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16052573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16052565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Prior to initiation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Moderate impairment (Child-Pugh class B): Initial: 0.3 mg twice daily (maximum: 1.2 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Severe impairment (Child-Pugh class C): Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      During therapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If ALT increases &gt;3 times ULN or baseline value: Recheck ALT during recommended timeframe per recommendations in manufacturer&rsquo;s labeling for confirmation. If ALT level confirmed or increasing, interrupt therapy and investigate potential cause.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If any liver test &ge;5 times ULN (with a normal baseline)",
"     <b>",
"      OR",
"     </b>",
"     &gt;5 times the baseline value (with an abnormal baseline):  Interrupt therapy and monitor liver tests more frequently per recommendations in manufacturer&rsquo;s labeling. If values return to normal or near normal, therapy may be reinitiated with extreme caution/monitoring only if another likely cause for hepatic effects discovered.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16355590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Signifor&reg;: 0.3 mg/mL (1 mL); 0.6 mg/mL (1 mL); 0.9 mg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15840328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM332633.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM332633.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16052574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by subcutaneous injection into the top of the thigh or abdomen. Do not inject into inflamed or irritated skin. Alternate the injection site. Do not use if vial contains particulates or solution is discolored.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15826669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Cushing's disease in patients for whom pituitary surgery is not an option or has not been curative",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16052357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pasireotide may be confused with lanreotide, octreotide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15898540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (28%), fatigue (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (40%), diabetes mellitus (18%), Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     increased (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (58%), nausea (52%), cholelithiasis (30%), abdominal pain (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Prothrombin time increased (2% to 33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reactions (17%; including pain, erythema, hematoma, hemorrhage, pruritus)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (10%), peripheral edema (10%), hypotension (7%), bradycardia (6%), QT prolongation (6%; &gt;480 msec 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Anxiety (9%), dizziness (9%), insomnia (9%), vertigo (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (8%), dry skin (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (10%), hypoglycemia (9%), type 2 diabetes mellitus (9%), adrenal insufficiency (6%), hypokalemia (6%), hypothyroidism (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Appetite decreased (10%), constipation (7%), lipase increased (7%), vomiting (7%), abdominal distension (6%), amylase increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (10%), GGT increased (10%), AST increased (6%), bilirubin increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Myalgia (9%), arthralgia (8%), back pain (6%), limb pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (9%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16052362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16052363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiac disorders: Bradycardia and QT prolongation have been observed with therapy. Use with caution in patients with preexisting cardiac disease, patients with risk factors for bradycardia (eg, heart block, history of significant bradycardia, receiving concomitant drugs known to cause bradycardia), and patients at risk for QT prolongation (eg, congenital long QT, recent MI, heart failure, hypokalemia, hypomagnesemia, receiving concomitant drugs known to cause QT prolongation). Obtain baseline ECG prior to therapy and consider continued  monitoring during therapy for an effect on the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval. Correct hypokalemia or hypomagnesemia prior to therapy and monitor during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cholelithiasis: May impair gallbladder, leading to gallstone formation; monitor patients for cholelithiasis with ultrasound prior to therapy and at 6- to 12-month intervals during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic effects: Increased liver enzymes have been reported; ALT, AST, and bilirubin should be monitored per recommendations in manufacturer&rsquo;s labeling. May require dosage interruption to investigate probable cause of confirmed or rising liver enzyme values; patients with significant elevations in liver function tests (&ge;5 times baseline values) require more frequent monitoring and extensive monitoring (ALT, AST, alkaline phosphatase, total bilirubin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperglycemia/diabetes: Inhibition of insulin and glucagon secretion may affect glucose regulation, leading to hyperglycemia. Exacerbation of glycemia occurred in almost all patients during the initial 2 weeks of therapy, including patients with normal glucose levels at baseline; diabetes and prediabetes has also been observed. Assess fasting blood glucose (FBG) levels or hemoglobin A1c (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) prior to initiation of therapy. Patients should also do self-monitoring and/or FBG weekly for the first 2-3 months, then periodically during use. If hyperglycemia occurs, initiation or dosage adjustment of antidiabetic therapy is recommended; if uncontrolled hyperglycemia persists despite antidiabetic therapy, consider dosage reduction or discontinuation of pasireotide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypocortisolism: Suppression of the adrenocorticotropic hormone (ACTH) from therapy may lead to hypocortisolism. Monitor patients for signs or symptoms of hypocortisolism (eg, anorexia, fatigue, hypoglycemia, hyponatremia, hypotension, nausea, vomiting, weakness). If symptoms occur, consider stopping or reducing the dose until symptoms improve. Glucocorticoid replacement therapy may also be needed temporarily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypothyroidism: Decreases (slight) in thyroid function have been observed during therapy; may require monitoring of thyroid function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: Prior to initiation, patients with poorly controlled or uncontrolled diabetes should have antidiabetic therapy optimized; exacerbation of glycemia commonly occurs with pasireotide use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; lower doses are recommended at therapy initiation in patients with moderate impairment (Child-Pugh class B). Use not recommended in patients with severe impairment (Child-Pugh class C).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; QTc-prolonging agents: Pasireotide may enhance the adverse/toxic effects of other QTc-prolonging agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Evaluate for treatment response with 24-hour urinary free cortisol levels and/or improvement in symptoms. Maximum reduction in urinary free cortisol levels is usually seen by 2 months of therapy. Therapy may cause inhibition of additional pituitary hormones (other than ACTH); additional monitoring for pituitary deficiency is advised (eg, TSH, free T",
"     <sub>",
"      4",
"     </sub>",
"     , GH, IGF-1), particularly in patients who have undergone transsphenoidal surgery and pituitary irradiation who are at an increased risk for deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16061149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16061147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: Somatostatin Analogs may decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Somatostatin Analogs may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Somatostatin Analogs may enhance the adverse/toxic effect of Pegvisomant. Specifically, this combination may increase the risk for significant elevations of liver enzymes.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16052358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16052359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16052360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16052361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if pasireotide is excreted into breast milk. The manufacturer recommends that caution be exercised when administering pasireotide to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Signifor Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg/mL (1 mL): $287.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg/mL (1 mL): $287.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9 mg/mL (1 mL): $287.67",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16052583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinary free cortisol (24-hour); fasting plasma glucose (FBG) or hemoglobin A1c (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) (prior to initiation); FBG and/or self-monitoring glucose (weekly for first 2-3 months then periodically during therapy), and FBG or Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     (following discontinuation as clinically appropriate); serum GH and IGF-1 (baseline then periodically); thyroid function (baseline then periodically); potassium and magnesium (prior to therapy then periodically during therapy); ECG (baseline and consider continued monitoring during treatment); gall bladder ultrasonography  (baseline, then every 6-12 months during therapy); signs and symptoms of  hypocortisolism (eg, weakness, fatigue, nausea, vomiting); heart rate",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Liver function tests (1-2 weeks after initiation, then monthly for 3 months, then every 6 months thereafter); more frequent testing may be necessary:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      If ALT",
"      <b>",
"       normal at baseline",
"      </b>",
"      and ALT increases 3-5 times ULN on therapy:",
"     </i>",
"     Repeat ALT within 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      If ALT",
"      <b>",
"       normal at baseline",
"      </b>",
"      and ALT increases &gt;5 times ULN on therapy:",
"     </i>",
"     Repeat ALT within 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      If ALT",
"      <b>",
"       abnormal at baseline",
"      </b>",
"      and ALT increases 3-5 times baseline values on therapy:",
"     </i>",
"     Repeat ALT within 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      If ALT",
"      <b>",
"       abnormal at baseline",
"      </b>",
"      and ALT increases &gt;5 times ULN on therapy:",
"     </i>",
"     Repeat ALT &lt;1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     ALT levels should be done in a laboratory capable of same-day results; if ALT levels are confirmed or rising, interrupt therapy and investigate cause.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     During therapy, if any liver test &ge;5 times ULN (with a normal baseline)",
"     <b>",
"      OR",
"     </b>",
"     &gt;5 times the baseline value (with an abnormal baseline), interrupt therapy and monitor ALT, AST, alkaline phosphatase, and total bilirubin weekly or more frequently. If values return to normal or near normal, therapy may be reinitiated with extreme caution/monitoring only if another likely cause for hepatic effects discovered.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16052547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic cyclohexapeptide analogue of somatostatin which is a peptide inhibitor of multiple endocrine, neuroendocrine, and exocrine mechanisms. Binds to somatostatin receptor (sst",
"     <sub>",
"      1-5",
"     </sub>",
"     ), with high affinity for the sst",
"     <sub>",
"      1",
"     </sub>",
"     , sst",
"     <sub>",
"      2",
"     </sub>",
"     , sst",
"     <sub>",
"      3",
"     </sub>",
"     subtypes, and highest affinity for the sst",
"     <sub>",
"      5",
"     </sub>",
"     subtype, resulting in inhibition of ACTH secretion which leads to decreased cortisol secretion.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16052549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : &gt;100 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily eliminated as unchanged drug hepatically (via biliary excretion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 0.25-0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (~40% to 56%, primarily as unchanged drug); urine (~6% to 10%, primarily as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Colao A, Petersenn S, Newell-Price J, et al, &ldquo;A 12-Month Phase 3 Study of Pasireotide in Cushing&rsquo;s Disease,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2012, 366(10):914-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/21/27989/abstract-text/22397653/pubmed\" id=\"22397653\" target=\"_blank\">",
"        22397653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Petersenn S, Schopohl J, Barkan A, et al, &ldquo;Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients With Acromegaly: A Randomized, Multicenter, Phase II Trial,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(6):2781-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/21/27989/abstract-text/20410233/pubmed\" id=\"20410233\" target=\"_blank\">",
"        20410233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shenouda M, Maldonado M, Wang Y, et al, &ldquo;An Open-Label Dose-Escalation Study of Once-Daily and Twice-Daily Pasireotide in Healthy Volunteers: Safety, Tolerability, and Effects on Glucose, Insulin, and Glucagon Levels,&rdquo;",
"      <i>",
"       Am J of Ther",
"      </i>",
"      , 2012 [epub ahead of print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/21/27989/abstract-text/22713526/pubmed\" id=\"22713526\" target=\"_blank\">",
"        22713526",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87457 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A18C3F2596-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27989=[""].join("\n");
var outline_f27_21_27989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355589\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826667\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052571\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052572\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052573\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052565\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355590\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15840328\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052574\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826669\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052357\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15898540\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052362\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052363\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16061149\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16061147\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052358\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052359\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052360\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052361\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570464\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052583\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052547\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052549\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87457\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87457|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/20/41285?source=related_link\">",
"      Pasireotide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_21_27990="Response-guided therapy for chronic hepatitis C virus infection";
var content_f27_21_27990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Response-guided therapy for chronic hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27990/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27990/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27990/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27990/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27990/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27990/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/21/27990/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15546056\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once antiviral therapy for chronic hepatitis C virus (HCV) infection has been started, the likelihood that a patient will achieve a sustained virologic response (SVR) can be predicted by the virologic response at 12 weeks of therapy, and probably even earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. The rapidity of the virologic response also appears to be an important predictor of an SVR. These observations have lead to attempts to tailor antiviral therapy based upon a patient's virologic response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H32984769#H32984769\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Changes in viral load during treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review response-guided therapy with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for chronic HCV infection. The use of peginterferon and ribavirin for the treatment of chronic HCV infection, the use of protease inhibitors for the treatment of patients with genotype 1, and an overview of the treatment of chronic HCV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15546494\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several terms are used to describe the response to antiviral therapy in patients with chronic HCV infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid virologic response (RVR): HCV RNA negativity after four weeks of treatment; if the HCV RNA remains negative at 12 weeks, it is known as an extended rapid virologic response (eRVR)",
"     </li>",
"     <li>",
"      Early virologic response (EVR): at least a 2 log",
"      <sub>",
"       10",
"      </sub>",
"      reduction in HCV RNA (a partial EVR) or HCV RNA negativity (a complete EVR) by week 12 of treatment",
"     </li>",
"     <li>",
"      Delayed virologic response: HCV RNA negativity at week 24 in patients who fail to achieve a complete EVR (such patients are also known as \"slow responders\")",
"     </li>",
"     <li>",
"      End of treatment response (EOT): HCV RNA negativity at the end of treatment",
"     </li>",
"     <li>",
"      Relapse: reappearance of HCV RNA in patients who were HCV RNA negative at the end of treatment",
"     </li>",
"     <li>",
"      Sustained virologic response (SVR): absence of HCV RNA by polymerase chain reaction six months after stopping treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15546063\">",
"    <span class=\"h1\">",
"     RATIONALE BEHIND RESPONSE-GUIDED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both an early virologic response (EVR) and a rapid virologic response (RVR) are associated with increased sustained virologic response (SVR) rates. As a result, a number of studies have evaluated whether treatment can be tailored based upon the virologic response at these time points. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H32984769#H32984769\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Changes in viral load during treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general strategies that have been tried are shortening therapy in those who achieve an RVR or EVR or lengthening therapy in those who do not. The data suggest that shorter treatment durations may be effective in patients with RVRs and EVRs, whereas results have been variable with regard to longer treatment durations in those without an EVR or RVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15546529\">",
"    <span class=\"h1\">",
"     STUDIES OF RESPONSE-GUIDED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have examined the possibility of altering the duration of therapy based upon whether a patient achieves a complete EVR or an RVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15546859\">",
"    <span class=\"h2\">",
"     Lengthening therapy for those who fail to achieve a complete EVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subset analyses of various studies have suggested that patients who have a delayed virologic response (\"slow responders\") may benefit from extending treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]. For example, in one randomized trial, patients were assigned to receive treatment for either 48 weeks (standard treatment) or for an additional 44 weeks after becoming HCV RNA negative (extended treatment group). Twenty of the patients became HCV RNA negative between weeks 16 and 24 (and thus did not achieve a complete EVR) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/14\">",
"     14",
"    </a>",
"    ]. The SVR rate in the extended treatment group was significantly higher than the in the standard treatment group (78 versus 9 percent).",
"   </p>",
"   <p>",
"    Meta-analyses have also found that extending treatment improves SVR rates in slow responders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. A meta-analysis of six randomized trials of treatment-naive patients with HCV genotype 1 found that extending treatment up to 72 weeks in slow responders significantly improved SVR rates compared with standard of care (36 versus 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/15\">",
"     15",
"    </a>",
"    ]. A second meta-analysis of six randomized trials (five of which were included in the prior meta-analysis) also found that patients who received 72 weeks of treatment had higher SVR rates compared with standard of care (39 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/16\">",
"     16",
"    </a>",
"    ]. Longer treatment may increase the risk of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/15\">",
"     15",
"    </a>",
"    ], though this has not been shown in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/8,9,16,18\">",
"     8,9,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether these findings apply to patients with genotype 1 who are receiving a protease inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    ) is not known. Based upon the available data, for patients with genotype 1 who are",
"    <strong>",
"     not",
"    </strong>",
"    able to receive a protease inhibitor we suggest that extended treatment (to 72 weeks) be considered in patients with a slow response, particularly if they are tolerating treatment reasonably well. If treatment is to be continued in patients who fail to achieve a complete EVR, then the viral load should be rechecked at 24 weeks. If the patient is still HCV RNA positive, then treatment should be discontinued as a response is unlikely. We suggest against extending treatment in patients with genotype 1 who are receiving a protease inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15546545\">",
"    <span class=\"h2\">",
"     Lengthening therapy in patients who fail to achieve an RVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies of patients receiving peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    suggest that extending treatment beyond 48 weeks in patients who fail to achieve an RVR increases SVR rates, while others show trends in that direction. A meta-analysis that included three randomized trials with 995 patients who failed to achieve an RVR found an improved SVR rate among those who received 72 weeks of treatment compared with those treated for 48 weeks (53 versus 42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individual trials have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial included a total of 510 treatment-na&iuml;ve patients receiving peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/7\">",
"       7",
"      </a>",
"      ]. HCV RNA was checked four weeks after starting treatment. Those who did not achieve an RVR were randomly assigned to 72 versus 48 weeks of treatment. Higher SVR rates were seen in patients who received 72 weeks of treatment compared with 48 weeks of treatment (45 versus 32 percent). The difference was even more pronounced in patients infected with HCV genotype 1 (44 versus 28 percent). The incidence of adverse events was similar, but treatment was more often discontinued in the group randomized to 72 weeks of treatment (36 versus 18 percent).",
"     </li>",
"     <li>",
"      A second trial included 113 patients (all genotype 1b) who were randomly assigned to combination treatment with peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for an additional 44 weeks after becoming HCV RNA negative (extended treatment; total duration 48 to 68 weeks) or for a set duration for 48 weeks (standard treatment) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/14\">",
"       14",
"      </a>",
"      ]. There was a trend toward higher SVR rates in the extended treatment group compared with the standard treatment group, but the results did not reach statistical significance (53 versus 36 percent, p = 0.07).",
"     </li>",
"     <li>",
"      Another trial of tailored therapy examined 289 patients with genotype 1 or 4 who did not have an RVR but did have an EVR [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/9\">",
"       9",
"      </a>",
"      ]. The patients were assigned to either 72 or 48 weeks of therapy with peginterferon alfa-2a plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      . Patients who received 72 weeks of therapy had a lower relapse rate compared with those treated for 48 weeks (19 versus 34 percent), but there was no statistically significant difference in SVR rates between the groups treated for 72 weeks and 48 weeks (59 versus 51 percent). The drop-out rate was significantly higher in the group treated for 72 weeks (32 versus 19 percent).",
"     </li>",
"     <li>",
"      A trial that included 696 patients with genotype 1 infection also showed a trend toward a benefit with extended treatment. The patients were randomly assigned to peginterferon plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for a duration of therapy based upon when the patient became HCV RNA negative (24 weeks if the HCV RNA was negative at week 4, 48 weeks if it was negative at week 8, or 72 weeks it was negative at week 12) for a duration of 48 weeks, regardless of when the HCV RNA became negative (standard of care) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/19\">",
"       19",
"      </a>",
"      ]. Of the 73 patients who became HCV RNA negative at 12 weeks, there was a trend toward a higher SVR rate in those treated for 72 weeks compared with those treated for 48 weeks (64 versus 38 percent, p = 0.07).",
"     </li>",
"     <li>",
"      A randomized trial with 236 patients with HCV genotype 1 or 4 failed to show a benefit for extended treatment. Patients were assigned to 24, 36, 48, or 72 weeks of treatment based upon changes in viral load [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/20\">",
"       20",
"      </a>",
"      ]. Sixty-one patients who were RNA positive at 4 weeks but negative at 8 weeks were assigned to either 48 or 36 weeks of treatment, and 84 patients who were RNA negative at 12 weeks were assigned to either 72 or 48 weeks of treatment. There was no difference in SVR rate based upon treatment duration for those who were RNA negative at 8 weeks (74 percent for 48 weeks of treatment and 73 percent for 36 weeks) or for those who were RNA negative at 12 weeks (40 percent for 72 weeks of treatment and 49 percent for 48 weeks).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IL28B polymorphisms may predict which patients will respond to a longer duration of therapy. In a trial of patients being treated for HCV genotype 1 or 4, 183 patients with IL28B genotyping data available failed to achieve an RVR but did achieve an early virologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/21\">",
"     21",
"    </a>",
"    ]. The patients were assigned to receive either 72 or 48 weeks of treatment with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Patients with the CC genotype (27 percent) had similar SVR rates with 72 and 48 weeks of treatment (80 versus 73 percent). Patients with the CT or TT genotype showed an increased SVR rate when treated for 72 weeks (81 versus 57 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15546553\">",
"    <span class=\"h2\">",
"     Shortening therapy for patients who achieve an RVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the studies listed above also compared standard versus shortened therapy for patients who achieved an RVR and suggested that shortening therapy in patients who achieve an RVR does not adversely affect SVR rates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/7,19,20\">",
"     7,19,20",
"    </a>",
"    ]. However, meta-analyses have found that shortening therapy decreases SVR rates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/16,22\">",
"     16,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One meta-analysis included seven studies with 807 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/19,23-28\">",
"     19,23-28",
"    </a>",
"    ]. It examined whether 24 weeks of treatment was sufficient in patients with HCV genotype 1 who achieved an RVR [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/22\">",
"     22",
"    </a>",
"    ]. The analysis found that patients treated for 24 weeks had a 14 percent lower SVR rate than those treated for 48 weeks, due primarily to a higher relapse rate. However, shorter therapy did appear effective in patients with low baseline HCV RNA levels (400,000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    or less). In that subgroup, there was no significant difference in SVR rates between 24 and 48 weeks of treatment.",
"   </p>",
"   <p>",
"    A second meta-analysis included 2062 patients with genotypes 2 and 3 who achieved an RVR and were assigned to either standard therapy with 24 weeks of peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    or a shorter course of therapy (ranging from 12 to 16 weeks). SVR rates were significantly lower among those who received shorter courses of therapy compared with those treated for 24 weeks (81 versus 87 percent).",
"   </p>",
"   <p>",
"    However, two trials that were not included in the meta-analyses suggested that shortening therapy in patients who achieve an RVR does not result in a lower SVR rate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the trial of 510 treatment-na&iuml;ve patients described above, 184 patients who achieved an RVR were randomly assigned to receive 24 or 48 weeks of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/7\">",
"       7",
"      </a>",
"      ]. The SVR rates were statistically similar between those treated for 24 and 48 weeks (79 versus 64 percent). The lowest SVR rate (64 percent) was seen in patients with genotype 1 and a baseline HCV RNA level greater than 800,000",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      who were treated for 48 weeks. The SVR rate was highest (94 percent) in patients with genotype 2 or 3 and a baseline HCV RNA levels of 800,000",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      or less who were treated for 24 weeks.",
"     </li>",
"     <li>",
"      In the trial of 236 patients with HCV genotype 1 or 4 described above, 50 patients were RNA negative at 4 weeks and assigned to either 24 or 48 weeks of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/20\">",
"       20",
"      </a>",
"      ]. There was no difference in SVR rate for those assigned to 24 or 48 weeks of treatment (84 versus 84 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27990/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2321658\">",
"    <span class=\"h2\">",
"     Response-guided therapy with newer agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response-guided therapy has also been studied with treatment regimens that include newer agents, such as",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protease inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    . Trials with these agents suggest that shorter courses of therapy may be appropriate for patients who achieve an RVR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link&amp;anchor=H148838144#H148838144\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\", section on 'HCV SPRINT trials'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link&amp;anchor=H148838100#H148838100\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\", section on 'ILLUMINATE trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15547004\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several terms are used to describe the response to antiviral therapy in patients with chronic HCV infection:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rapid virologic response (RVR): HCV RNA negativity after four weeks of treatment; if the HCV RNA remains negative at 12 weeks it is known as an extended rapid virologic response (eRVR)",
"     </li>",
"     <li>",
"      Early virologic response (EVR): at least a 2 log",
"      <sub>",
"       10",
"      </sub>",
"      reduction in HCV RNA (a partial EVR) or HCV RNA negativity (a complete EVR) by week 12 of treatment",
"     </li>",
"     <li>",
"      Delayed virologic response: HCV RNA negativity at week 24 in patients who fail to achieve a complete EVR (such patients are also known as \"slow responders\")",
"     </li>",
"     <li>",
"      End of treatment response (EOT): HCV RNA negativity at the end of treatment",
"     </li>",
"     <li>",
"      Relapse: reappearance of HCV RNA in patients who were HCV RNA negative at the end of treatment",
"     </li>",
"     <li>",
"      Sustained virologic response (SVR): absence of HCV RNA by polymerase chain reaction six months after stopping treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data suggest that lengthening treatment to 72 weeks in patients who fail to achieve a complete EVR increases SVR rates compared with 48 weeks of treatment. We suggest 72 weeks of treatment for patients with genotype 1 who are",
"      <strong>",
"       not",
"      </strong>",
"      able to receive a protease inhibitor and who do not achieve a complete EVR but are tolerating treatment reasonably well (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). We suggest against extending treatment in patients with genotype 1 who are receiving a protease inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15546859\">",
"       'Lengthening therapy for those who fail to achieve a complete EVR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data suggest a benefit of extending treatment beyond 48 weeks in patients who fail to achieve an RVR but who do achieve an EVR. However, given the side-effects and costs associated with treatment, as well as the modest benefit to extending treatment seen in many of the studies, we suggest continuing to treat patients for 48 weeks (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15546545\">",
"       'Lengthening therapy in patients who fail to achieve an RVR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shortening therapy to 24 weeks in patients with genotypes 1 and 4 who achieve an RVR appears to decrease sustained virologic response rates based upon the results of a meta-analysis, though more recent trials suggest that this may not be the case. Until more data become available, we suggest that such patients continue to be treated for 48 weeks (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15546553\">",
"       'Shortening therapy for patients who achieve an RVR'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/1\">",
"      Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/2\">",
"      Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/3\">",
"      Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/4\">",
"      Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/5\">",
"      Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/6\">",
"      Wong JB, Davis GL, McHutchison JG, et al. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/7\">",
"      S&aacute;nchez-Tapias JM, Diago M, Escart&iacute;n P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/8\">",
"      Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/9\">",
"      Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010; 138:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/10\">",
"      Marcellin P, Heathcote EJ, Crax&igrave; A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? J Hepatol 2007; 47:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/11\">",
"      Brouwer JT, Nevens F, Bekkering FC, et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol 2004; 40:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/12\">",
"      Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/13\">",
"      Sarrazin C, Schwendy S, M&ouml;ller B, et al. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology 2011; 141:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/14\">",
"      Ide T, Hino T, Ogata K, et al. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol 2009; 104:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/15\">",
"      Farnik H, Lange CM, Sarrazin C, et al. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2010; 8:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/16\">",
"      Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011; 54:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/17\">",
"      Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients. Cochrane Database Syst Rev 2012; 9:CD008516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/18\">",
"      Buti M, Lurie Y, Zakharova NG, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010; 52:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/19\">",
"      Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008; 47:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/20\">",
"      Lee SS, Sherman M, Ramji A, et, al. 36 versus 48 weeks of treatment with peginterferon alfa-2a plus ribavirin for genotype 1/4 patients with undetectable HCV RNA at week 8: Final results of a randomized multi-center study. Hepatology 2010; 52:359A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/21\">",
"      Scherzer TM, St&auml;ttermayer AF, Strasser M, et al. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. Hepatology 2011; 54:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/22\">",
"      Moreno C, Deltenre P, Pawlotsky JM, et al. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 2010; 52:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/23\">",
"      Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/24\">",
"      Brand&atilde;o C, Barone A, Carrilho F, et al. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. J Viral Hepat 2006; 13:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/25\">",
"      Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/26\">",
"      Berg T, Weich G, Teuber H, et, al. Evaluation of the efficacy of an 18 week short treatment duration in HCV type 1 infected patients based upon early viral kinetics: an aproach to recognise \"super-responders\". Hepatology 2006; 44:A346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/27\">",
"      Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27990/abstract/28\">",
"      Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47:1884.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15834 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27990=[""].join("\n");
var outline_f27_21_27990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15547004\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15546056\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15546494\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15546063\">",
"      RATIONALE BEHIND RESPONSE-GUIDED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15546529\">",
"      STUDIES OF RESPONSE-GUIDED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15546859\">",
"      Lengthening therapy for those who fail to achieve a complete EVR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15546545\">",
"      Lengthening therapy in patients who fail to achieve an RVR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15546553\">",
"      Shortening therapy for patients who achieve an RVR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2321658\">",
"      Response-guided therapy with newer agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15547004\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_21_27991="Who should be evaluated for renovascular or other causes of secondary hypertension?";
var content_f27_21_27991=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Who should be evaluated for renovascular or other causes of secondary hypertension?",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27991/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27991/contributors\">",
"     Stephen Textor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27991/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27991/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27991/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27991/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27991/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/21/27991/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient with hypertension depends upon the likely cause and also the degree of difficulty in achieving acceptable blood pressure control, since many forms of secondary hypertension cause \"treatment resistant\" hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients likely to have essential (idiopathic or primary) hypertension undergo a relatively limited evaluation because extensive laboratory testing is usually of little value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/422?source=see_link\">",
"     \"Initial evaluation of the hypertensive adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, patients who have clinical clues suggesting the possible presence of secondary hypertension should undergo a more extensive evaluation. If secondary hypertension is present, the most effective treatment strategy often is one that is focused upon the specific mechanism of the hypertension. In addition, some of these disorders can be cured, leading to partial or complete normalization of the blood pressure.",
"   </p>",
"   <p>",
"    Because it is not cost effective to perform a complete evaluation for secondary hypertension in every hypertensive patient, it is important to be aware of the clinical clues that suggest secondary hypertension. The identification of patients who should undergo an evaluation for secondary hypertension will be reviewed here. Testing methods for renovascular hypertension and treatment of unilateral and bilateral atherosclerotic renal artery stenosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29369?source=see_link\">",
"     \"Treatment of unilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=see_link\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CLINICAL CLUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of general clinical clues that are suggestive of secondary hypertension (",
"    <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe or resistant hypertension. Resistant hypertension is defined as the persistence of hypertension despite concurrent use of adequate doses of three antihypertensive agents from different classes, including a diuretic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36728?source=see_link&amp;anchor=H2#H2\">",
"       \"Definition, risk factors, and evaluation of resistant hypertension\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An acute rise in blood pressure developing in a patient with previously stable values.",
"     </li>",
"     <li>",
"      Age less than 30 years in non-obese, non-black patients with a negative family history of and no other risk factors (eg, obesity) for hypertension.",
"     </li>",
"     <li>",
"      Malignant or accelerated hypertension (eg, patients with severe hypertension and signs of end-organ damage such as retinal hemorrhages or papilledema, heart failure, neurologic disturbance, or acute kidney injury). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"       \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Proven age of onset before puberty.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these clues, there are other findings that specifically suggest renovascular or other forms of secondary hypertension as described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL CLUES FOR RENOVASCULAR HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renovascular hypertension is the most common potentially correctable cause of secondary hypertension. The incidence varies with the clinical setting. It probably occurs in less than 1 percent of patients with mild hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/2\">",
"     2",
"    </a>",
"    ]. By comparison, between 10 and 45 percent of white patients with severe or malignant hypertension have renal artery stenosis. Renal artery stenosis can be detected in many individuals with other manifestations of atherosclerosis, such as coronary artery disease (10 to 14 percent) and peripheral arterial and aortic disease (24 to 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For reasons that are not well understood, renovascular disease is less commonly identified in black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. As an example, the prevalence of renal artery stenosis in high-risk patients with severe or refractory hypertension was 27 to 45 percent in whites, compared with 8 to 19 percent in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/4\">",
"     4",
"    </a>",
"    ]. A more extreme disparity was found in a retrospective review of all patients diagnosed with renal artery stenosis at a single center, 95 percent of whom were white [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/5\">",
"     5",
"    </a>",
"    ]. However, two studies that prospectively screened individuals with or without clinical clues for renovascular hypertension found similar rates of renal artery stenosis in blacks and whites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Referral bias is a possible explanation for this discrepancy, given that blacks diagnosed with renal artery stenosis were more likely than whites to have severe or refractory hypertension and a history of stroke or myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a variety of findings associated with a higher likelihood of hypertension being secondary to renovascular disease. The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on Peripheral Artery Disease propose that diagnostic testing for renal artery stenosis is indicated in the following settings, assuming that a corrective procedure would be considered if renovascular disease were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/8\">",
"     8",
"    </a>",
"    ]. As with other vascular diseases, long-term management of these patients can be affected by the potential for progressive vascular occlusion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The general clinical clues for any cause of secondary hypertension as cited in the preceding section. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General clinical clues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Onset of severe hypertension (blood pressure &ge;180 mmHg systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      120 mmHg diastolic) after the age of 55 years.",
"     </li>",
"     <li>",
"      Unexplained deterioration of kidney function during antihypertensive therapy, especially an acute and sustained elevation in the serum creatinine concentration by more than 50 percent that occurs within one week of instituting therapy with an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=see_link\">",
"       \"Renal effects of ACE inhibitors in hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe hypertension in patients with diffuse atherosclerosis, particularly those over age 50. The relationship between atherosclerotic renal artery stenosis and atherosclerosis at other sites (eg, coronary, peripheral arterial) is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link&amp;anchor=H3#H3\">",
"       \"Chronic kidney disease associated with atherosclerotic renovascular disease\", section on 'Association with systemic atherosclerosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe hypertension in a patient with an unexplained atrophic kidney or asymmetry in renal sizes of &gt;1.5 cm. A unilateral small kidney (&le;9 cm) has a 75 percent association with the presence of large vessel occlusive disease.",
"     </li>",
"     <li>",
"      Severe hypertension in patients with recurrent episodes of acute (flash) pulmonary edema or refractory heart failure with impaired renal function [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/9\">",
"       9",
"      </a>",
"      ]. In a series of 55 patients with renovascular hypertension, for example, 23 percent had recurrent episodes of pulmonary edema requiring hospitalization. Flash pulmonary edema was more common in patients with bilateral compared with unilateral renal artery stenosis. The factors that contribute to acute decompensation include a hypertension-induced increase in afterload, inability of a hypertrophied left ventricle to relax in diastole (ie, diastolic with or without systolic dysfunction), sodium retention due to activation of the renin-angiotensin-aldosterone system, and associated renal dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"       \"Evaluation of acute decompensated heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A systolic-diastolic abdominal bruit that lateralizes to one side. This finding has a sensitivity of approximately 40 percent (and is therefore absent in many patients) but has a specificity as high as 99 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/12\">",
"       12",
"      </a>",
"      ]. Systolic bruits alone are more sensitive but less specific [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/12\">",
"       12",
"      </a>",
"      ]. The patient should be supine, moderate pressure should be placed on the diaphragm of the stethoscope, and auscultation should be performed in the epigastrium and all four abdominal quadrants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, radiologic testing to confirm the presence of renal artery stenosis",
"    <strong>",
"     may",
"    </strong>",
"    be indicated in patients for whom the history is suggestive (based upon a general assessment of clinical risk factors)",
"    <strong>",
"     and",
"    </strong>",
"    in whom a corrective procedure will be performed if renovascular disease is detected. There is little value and potential harm from radiologic testing if the patient is not a candidate for a corrective procedure. Imaging methods for renovascular hypertension, and how one makes the choice between medical and interventional therapy in such patients, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29369?source=see_link\">",
"     \"Treatment of unilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=see_link\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26631?source=see_link\">",
"     \"Treatment of fibromuscular dysplasia of the renal arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL CLUES FOR OTHER FORMS OF SECONDARY HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of secondary hypertension also must be excluded in the appropriate settings (",
"    <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Primary kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of primary kidney disease is suggested by an elevated serum creatinine concentration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an abnormal urinalysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=see_link\">",
"     \"Overview of hypertension in acute and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3174297\">",
"    <span class=\"h2\">",
"     Primary aldosteronism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main clinical clue suggestive of primary aldosteronism is otherwise unexplained or easily provoked hypokalemia due to urinary potassium wasting. However, more than one-half of patients have a normal serum potassium concentration. Primary aldosteronism should also be suspected in the presence of slight hypernatremia, drug-resistant hypertension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension with an adrenal incidentaloma. Measurement of the ratio of the plasma aldosterone concentration to plasma renin activity can help identify such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/13\">",
"     13",
"    </a>",
"    ], although inappropriate elevation of aldosterone is also a common feature in obese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link&amp;anchor=H22#H22\">",
"     \"The adrenal incidentaloma\", section on 'Aldosteronomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptives often raise the blood pressure within the normal range but can induce overt hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37859?source=see_link\">",
"     \"Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytoma should be suspected if there are paroxysmal elevations in blood pressure (which may be superimposed upon stable chronic hypertension), particularly if associated with the triad of headache (usually pounding), palpitations, and sweating. In addition, patients with drug-resistant hypertension and those with an adrenal incidentaloma should be evaluated for pheochromocytoma. Patients identified with pheochromocytoma are rarely asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link&amp;anchor=H21#H21\">",
"     \"The adrenal incidentaloma\", section on 'Pheochromocytoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cushing's syndrome (including that due to glucocorticoid administration) is usually suggested by the classic physical findings of cushingoid facies, central obesity, proximal muscle weakness, and ecchymoses. However, Cushing's or subclinical Cushing's syndrome should also be suspected in patients with drug-resistant hypertension and in those with an adrenal incidentaloma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link&amp;anchor=H18#H18\">",
"     \"The adrenal incidentaloma\", section on 'Subclinical Cushing's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sleep apnea syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sleep apnea syndrome is most commonly identified in obese men who snore loudly while asleep. These patients have repeated apneic episodes at night due to passive collapse of the pharyngeal muscles during inspiration, such that the airway becomes occluded from the apposition of the tongue and soft palate against the posterior oropharynx. A variety of other symptoms may be seen including headache, daytime somnolence and fatigue, morning confusion with difficulty in concentration, personality changes, depression, persistent systemic hypertension, and potentially life-threatening cardiac arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with obstructive sleep apnea often retain sodium and fail to respond optimally to antihypertensive drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/15\">",
"     15",
"    </a>",
"    ]. Correction of the sleep apnea may improve blood pressure control [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link&amp;anchor=H2#H2\">",
"     \"Cardiovascular effects of obstructive sleep apnea\", section on 'Systemic hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coarctation of the aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coarctation of the aorta is one of the major causes of secondary hypertension in young children but may first be detected in adulthood (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70656 graphicRef79548 \" href=\"UTD.htm?43/32/44547\">",
"     image 1A-B",
"    </a>",
"    ). The classic findings are hypertension in the upper extremities, diminished or delayed femoral pulses (\"brachial-femoral delay\"), and low or unobtainable arterial blood pressure in the lower extremities. In addition, a prominent \"to-and-fro machinery murmur\" from the aorta may be heard over the posterior chest.",
"   </p>",
"   <p>",
"    Patient age, the site of origin of the left subclavian artery, and the severity of the coarctation affect the pattern of blood pressure findings. As an example, the origin of the left subclavian artery is just distal to the coarctation in some patients; in this setting, the left brachial pulse is diminished compared to the right and equal to the femoral pulse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the 2003 JNC 7 report on hypertension and the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines for adults with congenital heart disease, patients with hypertension should be evaluated for possible coarctation of the aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. This involves palpating the brachial and femoral pulses simultaneously to assess amplitude and timing, looking for diminished arterial pulses and brachial-femoral delay. In addition, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended measurement of supine bilateral arm (brachial artery) blood pressures and prone right or left supine leg (popliteal artery) blood pressures to search for differential pressures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link&amp;anchor=H2#H2\">",
"     \"Examination of the arterial pulse\", section on 'Unequal or delayed pulses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other endocrine disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension may be associated with both hypothyroidism, which may be suspected because of suggestive symptoms or an elevated serum thyroid stimulating hormone level, and primary hyperparathyroidism. The latter is most often suspected because of otherwise unexplained hypercalcemia, which may affect vascular reactivity, day-night blood pressure regulation, and renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27991/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/20/37186?source=see_link\">",
"       \"Patient information: Renovascular hypertension (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"       \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"       \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"       \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9686035\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is not cost effective to perform a complete evaluation for secondary hypertension in every hypertensive patient. Thus, it is important to be aware of the clinical clues that suggest secondary hypertension. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a number of general clinical clues that are suggestive of secondary hypertension (",
"      <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H2\">",
"       'General clinical clues'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe or resistant hypertension. Resistant hypertension is defined as the persistence of hypertension despite concurrent use of adequate doses of three antihypertensive agents from different classes, including a diuretic.",
"     </li>",
"     <li>",
"      An acute rise in blood pressure developing in a patient with previously stable values.",
"     </li>",
"     <li>",
"      Age less than 30 years in non-obese, non-black patients with a negative family history of and no other risk factors (eg, obesity) for hypertension.",
"     </li>",
"     <li>",
"      Malignant or accelerated hypertension (eg, patients with severe hypertension and signs of end-organ damage such as retinal hemorrhages or papilledema, heart failure, neurologic disturbance, or acute kidney injury).",
"     </li>",
"     <li>",
"      Proven age of onset before puberty.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to these clues, there are other findings that specifically suggest renovascular hypertension, such as an acute sustained elevation in the serum creatinine by more than 50 percent within a week of instituting therapy with an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, severe hypertension in a patient with an unexplained atrophic kidney or asymmetry in renal sizes, severe hypertension in a patient with recurrent episodes of acute (flash) pulmonary edema or refractory heart failure with impaired renal function, and severe hypertension in conjunction with a systolic-diastolic abdominal bruit that lateralizes to one side. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical clues for renovascular hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other causes of secondary hypertension, including primary kidney disease, primary aldosteronism, use of oral contraceptives, pheochromocytoma, Cushing's syndrome, sleep apnea syndrome, and coarctation of the aorta must also be excluded in the appropriate settings (",
"      <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical clues for other forms of secondary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/1\">",
"      Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/2\">",
"      Lewin A, Blaufox MD, Castle H, et al. Apparent prevalence of curable hypertension in the Hypertension Detection and Follow-up Program. Arch Intern Med 1985; 145:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/3\">",
"      Textor SC, Lerman L. Renovascular hypertension and ischemic nephropathy. Am J Hypertens 2010; 23:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/4\">",
"      Davis BA, Crook JE, Vestal RE, Oates JA. Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy. N Engl J Med 1979; 301:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/5\">",
"      Novick AC, Zaki S, Goldfarb D, Hodge EE. Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients. J Vasc Surg 1994; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/6\">",
"      Hansen KJ, Edwards MS, Craven TE, et al. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg 2002; 36:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/7\">",
"      Svetkey LP, Kadir S, Dunnick NR, et al. Similar prevalence of renovascular hypertension in selected blacks and whites. Hypertension 1991; 17:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/8\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/9\">",
"      Kane GC, Xu N, Mistrik E, et al. Renal artery revascularization improves heart failure control in patients with atherosclerotic renal artery stenosis. Nephrol Dial Transplant 2010; 25:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/10\">",
"      Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/11\">",
"      Messerli FH, Bangalore S, Makani H, et al. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome. Eur Heart J 2011; 32:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/12\">",
"      Turnbull JM. The rational clinical examination. Is listening for abdominal bruits useful in the evaluation of hypertension? JAMA 1995; 274:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/13\">",
"      Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005; 18:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/14\">",
"      Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/15\">",
"      Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001; 19:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/16\">",
"      Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol 2008; 52:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/17\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/18\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/19\">",
"      Streeten DH, Anderson GH Jr, Howland T, et al. Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension. Hypertension 1988; 11:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/20\">",
"      Lind L, Jacobsson S, Palm&eacute;r M, et al. Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. J Intern Med 1991; 230:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27991/abstract/21\">",
"      Kanbay M, Isik B, Akcay A, et al. Relation between serum calcium, phosphate, parathyroid hormone and 'nondipper' circadian blood pressure variability profile in patients with normal renal function. Am J Nephrol 2007; 27:516.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3862 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27991=[""].join("\n");
var outline_f27_21_27991=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9686035\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CLINICAL CLUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL CLUES FOR RENOVASCULAR HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL CLUES FOR OTHER FORMS OF SECONDARY HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Primary kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3174297\">",
"      Primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sleep apnea syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9686035\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3862\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3862|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/18/34095\" title=\"diagnostic image 1A\">",
"      Coarctation aorta PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/33/42527\" title=\"diagnostic image 1B\">",
"      Coarctation aorta PA angiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3862|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/38/42604\" title=\"table 1\">",
"      Features of secondary HTN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=related_link\">",
"      Chronic kidney disease associated with atherosclerotic renovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36728?source=related_link\">",
"      Definition, risk factors, and evaluation of resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37859?source=related_link\">",
"      Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=related_link\">",
"      Establishing the diagnosis of renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/422?source=related_link\">",
"      Initial evaluation of the hypertensive adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/20/37186?source=related_link\">",
"      Patient information: Renovascular hypertension (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=related_link\">",
"      Renal effects of ACE inhibitors in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=related_link\">",
"      Treatment of bilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26631?source=related_link\">",
"      Treatment of fibromuscular dysplasia of the renal arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29369?source=related_link\">",
"      Treatment of unilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_21_27992="Chlamydia trachomatis infections in the newborn";
var content_f27_21_27992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chlamydia trachomatis infections in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27992/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27992/contributors\">",
"     Mohan Pammi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27992/contributors\">",
"     Margaret R Hammerschlag, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27992/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27992/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27992/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27992/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/21/27992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydia trachomatis (C. trachomatis) is the most common cause of sexually transmitted genital infections in the United States. Infants born vaginally to infected mothers with genital disease are at risk for acquiring C. trachomatis, which usually presents as conjunctivitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pneumonia.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of C. trachomatis conjunctivitis and pneumonia in the newborn and young infant are reviewed here.",
"   </p>",
"   <p>",
"    Pneumonia in older children, other disorders caused by Chlamydia, and the possible role of infection in preterm delivery are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=see_link\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) species in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. trachomatis is primarily transmitted to newborns via exposure to an infected mother's genital flora during vaginal birth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/1\">",
"     1",
"    </a>",
"    ]. There are case reports documenting chlamydial infection in infants born after cesarean delivery with ruptured membranes and more rarely, intact membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The latter condition indicates either a transmembrane or a transplacental transmission of the infection.",
"   </p>",
"   <p>",
"    There are 15 serovariants of C. trachomatis. Neonatal infection is usually caused by C. trachomatis serovariants D through K, which are the primary serotypes causing genital disease in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a brief review of the prevalence of C. trachomatis in pregnant women. The prevalence and risk factors for C. trachomatis infection in women in the general population are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link&amp;anchor=H4#H4\">",
"     \"Genital Chlamydia trachomatis infections in women\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of C. trachomatis in pregnant women ranges from 2 to 20 percent depending on the population screened [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Similar to the increased prevalence of C. trachomatis in adolescent and young adult women in the general population, the highest prevalence rate in pregnancy occurs in adolescent and young adult women. This was illustrated in a British study that screened 1216 pregnant women for C. trachomatis infection by testing for the presence of the organism by ligase chain reaction from self-administered vaginal swab or first-pass urine specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/9\">",
"     9",
"    </a>",
"    ]. The overall prevalence of infection was 2.4 percent. In women less than 25 years of age and adolescents, the prevalence increased to 8.6 and 14.3 percent, respectively. In another study of 203 pregnant adolescents from the United States, 18 percent had C. trachomatis infection in the third trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not specifically studied in pregnant women, other risk factors for C. trachomatis infection in sexually active women include multiple sex partners, non-use of barrier contraceptives, concurrent or prior sexually transmitted disease, and anatomic factors (eg, cervical friability or cervical ectopy). Presumably, these risk factors for C. trachomatis infection seen in the general population are also likely to be risk factors for infection in pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link&amp;anchor=H6#H6\">",
"     \"Genital Chlamydia trachomatis infections in women\", section on 'Risk factors for infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of acquiring C. trachomatis in an infant born vaginally to a woman with chlamydial cervicitis is approximately 50 percent but has been reported to be as high as 60 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/7,8,11-17\">",
"     7,8,11-17",
"    </a>",
"    ]. However, this estimation includes newborns with asymptomatic infection of the nasopharynx or only serologic evidence of infection. The rate of symptomatic chlamydial infection in infants born to C. trachomatis infected mothers is lower. Based upon positive cultures for C. trachomatis in symptomatic infants, the risk for neonatal acquired conjunctivitis is between 20 to 50 percent, and for pneumonia 5 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/6,11-13,16,17\">",
"     6,11-13,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discrepancy of transmission rate based upon detection methods and location of screening in at risk infants is best illustrated by a prospective study of 5531 pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/11\">",
"     11",
"    </a>",
"    ]. Positive cervical cultures for C. trachomatis were detected in 262 women (4.7 percent) and 131 of their infants were followed prospectively. Sixty percent of these infants demonstrated positive serology for C. trachomatis and in 36 percent of infants, the organism was isolated from cultures of the nasopharynx, conjunctivae, rectum, and vagina. Culture-positive conjunctivitis was diagnosed in 23 of these 131 infants (18 percent) and pneumonia in 21 (16 percent). Rectal and vaginal colonization was demonstrated in 14 percent.",
"   </p>",
"   <p>",
"    In a decision analysis evaluating prophylactic treatment for infants exposed to maternal Chlamydia infection, a review of the literature estimated the prevalence of conjunctivitis and pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/17\">",
"     17",
"    </a>",
"    ]. In 13 studies published from 1977 to 1994, 156 of 1055 infants (15 percent) exposed to maternal chlamydial infection developed conjunctivitis. In 10 studies, 42 of 507 infants (7 percent) exposed to maternal infection developed pneumonia. These results are limited by the inclusion of observed case series with prospective cohort studies.",
"   </p>",
"   <p>",
"    While vaginal birth carries the highest risk of transmission, there is a small risk of acquiring infections in infants born by cesarean delivery both with premature rupture of membranes and intact membranes. In one study of 141 exposed infants, for example, C. trachomatis was isolated from 58 of 125 infants delivered vaginally, 2 of 10 delivered by cesarean delivery with rupture of membranes, and 1 of 6 delivered by cesarean delivery without rupture of membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent clinical manifestation of C. trachomatis infection in the newborn is conjunctivitis. The condition is sometimes referred to as inclusion conjunctivitis of the newborn (ICN) or inclusion blennorrhea.",
"   </p>",
"   <p>",
"    The incubation period for C. trachomatis conjunctivitis is 5 to 14 days after delivery. Presentation before five days is unusual but has been reported to occur earlier in infants born to mothers with premature rupture of the membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical findings of conjunctivitis range from mild swelling with a watery eye discharge, which becomes mucopurulent, to marked swelling of the eyelids with red and thickened conjunctivae (chemosis) (",
"    <a class=\"graphic graphic_picture graphicRef74760 \" href=\"UTD.htm?4/46/4839\">",
"     picture 1",
"    </a>",
"    ). A pseudomembrane may form as the exudate adheres to conjunctiva. The conjunctivae may also be very friable resulting in bloody discharge. In a retrospective study of 90 infants from Hong Kong with conjunctivitis, blood-stained eye discharge was found to have high specificity and positive predictive value for chlamydial conjunctivitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/19\">",
"     19",
"    </a>",
"    ]. A membrane of granulation tissue (micropannus) may form, especially if the patient is untreated for more than two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of conjunctivitis usually results in healing without complications. However, untreated infection may persist for months and cause corneal and conjunctival scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among infants born to mothers with cervical C. trachomatis infection, 5 to 30 percent develop pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/11-13,16,17\">",
"     11-13,16,17",
"    </a>",
"    ]. Approximately one-half of these infants have a history of conjunctivitis.",
"   </p>",
"   <p>",
"    Pneumonia due to C. trachomatis is recognized in most affected infants between 4 and 12 weeks of age, although essentially all are symptomatic before 8 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/18\">",
"     18",
"    </a>",
"    ]. Some infants may have upper respiratory tract symptoms as early as two weeks of age. Cough and nasal congestion without significant discharge are common, although occasional infants may have thick nasal secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/24\">",
"     24",
"    </a>",
"    ]. Otitis media may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H20#H20\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Other pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients usually are afebrile or have minimal fever. Characteristic features are a staccato cough that may occur in paroxysms and tachypnea, although these are not universally present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/6\">",
"     6",
"    </a>",
"    ]. Rales are often present on auscultation of the lungs; however, wheezing is uncommon. The liver and spleen may be easily palpable because of the hyperinflated lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/25\">",
"     25",
"    </a>",
"    ]. Preterm infants may have apneic spells associated with the infection. C. trachomatis has been isolated from tracheal secretions of preterm infants with pneumonia in the first week after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=see_link\">",
"     \"Management of apnea of prematurity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The white blood cell count is typically normal. However, an elevated eosinophil count (300 to",
"    <span class=\"nowrap\">",
"     400/microL)",
"    </span>",
"    is frequently seen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arterial blood gas analysis often shows mild to moderate hypoxemia. This may persist for weeks after the acute infection has resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chest radiograph typically shows hyperinflation with bilateral, symmetrical, interstitial infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"gold standard\" for diagnosis of neonatal C. trachomatis is isolation by culture. In addition, there are several nonculture methods, such as nucleic acid amplification tests. While these nonculture techniques have a high sensitivity and specificity when compared to culture, there are insufficient data in newborns to replace culture as a primary means of diagnosis. Nevertheless, these tests may be useful when a rapid diagnosis is desirable as the turnaround time for results can be considerably shorter than culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Indications for testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. trachomatis should be suspected in an infant less than one month of age with conjunctivitis, if there is the possibility of exposure to the organism, specifically if the mother has a history of untreated C. trachomatis infection, or no prenatal care. If there has been no prenatal care or a maternal history of Neisseria gonorrhoeae (N. gonorrhoeae), the exudate also should be examined with Gram stain and cultured using selective medium to detect N. gonorrhoeae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=see_link\">",
"     \"Gonococcal infection in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of C. trachomatis infection should be considered in an infant less than three months of age with pneumonia, if the mother has history of untreated infection or no prenatal care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Specimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns suspected of chlamydial infection should have both conjunctival and nasopharyngeal samples taken.",
"   </p>",
"   <p>",
"    Conjunctival specimens for C. trachomatis testing should be obtained from the everted eyelid using aluminum shafted Dacron-tipped swab or a swab specified by the manufacturer's test kit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/28\">",
"     28",
"    </a>",
"    ]. The specimens must include conjunctival epithelial cells because C. trachomatis is an obligate intracellular organism. Exudates are not adequate for testing. Other swabs, such as wood shafts or tips with calcium alginate are",
"    <strong>",
"     not",
"    </strong>",
"    recommended as they inhibit the growth of the organism.",
"   </p>",
"   <p>",
"    In infants with pneumonia, testing for C. trachomatis should be performed on specimens obtained from the nasopharynx. Tracheal aspirates can be sent in patients who are intubated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diagnostic methods",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture of the organism is the \"gold standard\" for diagnosing neonatal C. trachomatis conjunctivitis and pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/29\">",
"     29",
"    </a>",
"    ]. The specificity and sensitivity of culture is nearly 100 percent with adequate sampling, appropriate transport, and a skilled laboratory staff.",
"   </p>",
"   <p>",
"    Specimens for C. trachomatis testing should be obtained using an aluminum shafted Dacron-tipped swab [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The specimen should be transported immediately at 2 to 8&ordm;C and processed within 24 hours. If processing is delayed, the specimen should be kept at &ndash;70&ordm;C. Storage at &ndash;20&ordm;C or in frost-free freezers kills the organism and is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. The sample is inoculated into tissue culture. After 48 to 72 hours, positive confirmation of C. trachomatis is made by microscopic identification using a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    conjugated species-specific monoclonal antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/18,29,32\">",
"     18,29,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nucleic acid amplification tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleic acid amplification (NAAT) methodology consists of amplifying C. trachomatis DNA or RNA sequences. There are currently three FDA approved NAATs for detection of C. trachomatis: polymerase chain reaction (PCR, Amplicor, Roche Diagnostics), transcription-mediated amplification (TMA, GenProbe), or strand displacement amplification (SDA, ProbeTec, Becton-Dickson). Studies have found that NAATs have high sensitivity and specificity compared to culture especially in the diagnosis of genital infections in sexually active women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/32\">",
"     32",
"    </a>",
"    ]. However, none of the currently available NAATs have Food and Drug Administration (FDA) approval for use in conjunctival or nasopharyngeal specimens from infants.",
"   </p>",
"   <p>",
"    Nevertheless, there are supportive data showing the efficacy of these tests. Results of one study published in 1997 and one published in 2008 suggested that polymerase chain reaction (PCR) performed very well compared with culture for detection of",
"    <em>",
"     C. trachomatis",
"    </em>",
"    in conjunctival specimens from infants with conjunctivitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Infants with",
"    <em>",
"     C. trachomatis",
"    </em>",
"    conjunctivitis usually have very high numbers of organisms present, and it is easy to obtain an adequate specimen. As a result, it is not unreasonable to expect that the currently available NAATs will perform well for the diagnosis of neonatal chlamydial conjunctivitis similar to that of the antigen detection methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Antigen detection methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;These methods include direct fluorescent antibody (DFA) and enzyme immunoassay (EIA) tests. Sensitivity and specificity with conjunctival specimens is high. Many of the earlier antigen detection tests, including direct fluorescent antibody staining (DFA) and enzyme immunoassays performed well with conjunctival specimens, with sensitivities and specificities of 97 to 98 percent. Performance was not as robust with nasopharyngeal specimens, probably reflecting the lower number of organisms and variation with specimen.",
"   </p>",
"   <p>",
"    FDA has approved antigen detection methods for the diagnosis of neonatal conjunctivitis and pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. There are only two commercially available antigen detection tests in the United States, (Pathfinder&reg; Chlamydia DFA and EIA Microplate). These tests have largely been replaced by NAATs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of C trachomatis pneumonia can be made by serum antibody determination using the microimmunofluorescence (MIF) method. A serum titer of C. trachomatis-specific immunoglobulin M of &ge; 1:32 is considered diagnostic of neonatal trachomatis pneumonia. Serum antibody testing is",
"    <strong>",
"     not",
"    </strong>",
"    reliable for conjunctivitis. However, this test is not FDA approved, difficult to perform, and not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment for chlamydial conjunctivitis should be based upon a positive diagnostic test. By contrast, initial therapy for chlamydial pneumonia should be initiated on a presumptive diagnosis based upon clinical and radiographic findings until diagnostic tests results are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Choice of antibiotic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics (AAP) Committee on Infectious Disease and the Centers for Disease Control (CDC) recommend oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day PO in four divided doses) for 14 days for either chlamydial conjunctivitis or pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/6,28,34\">",
"     6,28,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical therapy of chlamydial conjunctivitis is",
"    <strong>",
"     not",
"    </strong>",
"    effective and there is a high failure rate compared to oral therapy in eradicating conjunctival infection and does not eradicate nasopharyngeal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/6,12,35\">",
"     6,12,35",
"    </a>",
"    ]. This was illustrated in a randomized controlled study of infants with chlamydial conjunctivitis that reported eradication of the organism in 14 of 15 patients treated with oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    versus persistent conjunctival infection in eight infants and nasopharyngeal colonization in 3 of 14 infants treated with topical ointment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/35\">",
"     35",
"    </a>",
"    ]. These results demonstrate that oral compared to topical erythromycin provides better resolution of conjunctivitis and eradication C. trachomatis from the nasopharynx.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     Azithromycin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    PO) for a three day course may be effective in treating chlamydial conjunctivitis. In one study, three of five infants with conjunctivitis treated with single dose of azithromycin therapy became culture-negative with resolution of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/36\">",
"     36",
"    </a>",
"    ]. Eight infants were treated once daily for three days. In six of these patients, infection resolved and cultures became negative, one remained culture-positive until",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    was administered although symptoms improved, and one was lost to follow-up.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     Erythromycin",
"    </a>",
"    is effective in only 80 to 90 percent of cases of conjunctivitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/6,28,34\">",
"     6,28,34",
"    </a>",
"    ]. Treated infants should be followed carefully as a second course may be required if the infection has not resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/28\">",
"     28",
"    </a>",
"    ]. Infants who fail an initial course of erythromycin should be retreated with a second course of erythromycin (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day PO in four divided doses) for 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Risk of pyloric stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    to young infants for postexposure prophylaxis or treatment of pertussis has been associated with infantile hypertrophic pyloric stenosis (IHPS). The greatest risk appears to occur when infants are given the medication within the first two weeks of life. There are case reports of IHPS associated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    , however, it is not known if there is a risk of IHPS with azithromycin or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    similar to that reported with the use of erythromycin in infants with pertussis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=see_link&amp;anchor=H3#H3\">",
"     \"Infantile hypertrophic pyloric stenosis\", section on 'Macrolide antibiotics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\", section on 'Choice of agent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because alternative therapies for C. trachomatis in the newborn are not well studied, the AAP and CDC continue to recommend",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    to treat neonatal Chlamydia infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/6\">",
"     6",
"    </a>",
"    ]. Parents should be advised about the potential risk for IHPS and infants should be observed closely for signs of intestinal obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=see_link&amp;anchor=H3#H3\">",
"     \"Infantile hypertrophic pyloric stenosis\", section on 'Macrolide antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment of the mother",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infant's mother and her sexual partner(s) should be evaluated and treated for C. trachomatis infection. They also should be evaluated for other sexually treated diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Maternal screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic screening and treatment of chlamydial infection in pregnant women has resulted in a dramatic decrease in perinatal chlamydial infections in the United States.",
"   </p>",
"   <p>",
"    In countries, such as the Netherlands and China, prenatal screening and treatment is not part of the routine prenatal care, and perinatal transmitted C. trachomatis is a common cause of neonatal conjunctivitis and respiratory illness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. This practice continues even though the rate of C. trachomatis infection among pregnant women exceeds 5 percent in Rotterdam.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from Rotterdam, C. trachomatis was responsible for approximately 64 percent of the cases of neonatal conjunctivitis seen in a large university-affiliated hospital from 1999 through 2001 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study from the same institution, respiratory C. trachomatis infection was confirmed in 10 of 148 infants (7 percent) less than six months of age with respiratory complaints who presented during the calendar year 2002 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/40\">",
"       40",
"      </a>",
"      ]. These patients were screened for viral, C. trachomatis and Mycoplasma pneumoniae infections using PCR, viral culture, and direct immunofluorescence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) recommends that all pregnant women be screened for Chlamydia at the first prenatal visit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/28\">",
"     28",
"    </a>",
"    ]. Women under age 25 and those at increased risk for chlamydial infection should have repeat testing in the third trimester. Pregnant women who test positive for C. trachomatis should be treated with appropriate antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=see_link&amp;anchor=H1790568#H1790568\">",
"     \"Screening for Chlamydia trachomatis\", section on 'Pregnant women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these recommendations, testing and appropriate treatment frequently are not always performed. In one retrospective study of 55 mothers who delivered infants with chlamydial infection, 12 (22 percent) had not received prenatal testing for the organism and 15 patients (27 percent) who had documented C. trachomatis were not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/41\">",
"     41",
"    </a>",
"    ]. A study from the CDC reported 61 percent of pregnant women from 10 sites across the United States were screened for",
"    <em>",
"     C. trachomatis",
"    </em>",
"    from 2003 to 2004. The overall positivity rate was 3.3 percent (range 0.3 to 4.7 percent), and 83 percent of pregnant women with positive tests were treated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prophylaxis against conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most of the United States, neonatal prophylaxis against gonococcal conjunctivitis is routinely performed at birth, and required in the majority of states. However, neonatal ocular prophylaxis is not effective in preventing neonatal chlamydial conjunctivitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/31,43-47\">",
"     31,43-47",
"    </a>",
"    ]. The diagnosis and treatment of chlamydial infections in pregnant women is the best method for preventing chlamydial disease.",
"   </p>",
"   <p>",
"    Ophthalmia Neonatorum prophylaxis for gonococcal conjunctivitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the routine management of the healthy newborn infant\", section on 'Eye care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    prophylaxis for asymptomatic neonates exposed to untreated maternal C. trachomatis infection is not cost-effective. A decision tree analysis of cost-benefits in a large hypothetical cohort of infants concluded that watchful waiting was more cost effective than prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27992/abstract/17\">",
"     17",
"    </a>",
"    ]. This analysis was based upon a literature review of the estimated prevalence rate of neonatal C. trachomatis infection, and cost of oral erythromycin prophylaxis including potential cases of pyloric stenosis versus cost of treatment of neonatal infection. One limitation of this study is that the estimated prevalence rate was based upon data prior to the initiation of systematic screening and treatment of pregnant women with C. trachomatis infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/34/3618?source=see_link\">",
"       \"Patient information: Newborn conjunctivitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants who are born vaginally to mothers with untreated genital Chlamydia trachomatis (C. trachomatis) infection are at risk for developing C. trachomatis conjunctivitis (15 to 50 percent)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pneumonia (5 to 20 percent). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common clinical manifestation of neonatal C. trachomatis infection is conjunctivitis, which usually presents between 5 to 14 days of life. Symptoms range from mild swelling with a watery eye discharge, which becomes mucopurulent, to marked swelling of the eyelids with red and thickened conjunctivae (chemosis). Untreated infants may have persistent conjunctivitis for months that may result in corneal and conjunctival scarring. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Conjunctivitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal C. trachomatis pneumonia presents between 4 to 11 weeks of age, although most infants are symptomatic before eight weeks. Patients are usually afebrile or have minimal fever with a staccato cough. Many infants also have conjunctivitis. Apnea may be seen in infected preterm infants. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gold standard for diagnosis of neonatal C. trachomatis is culture. Nucleic acid amplification tests are non-culture diagnostic tools with a high sensitivity and specificity compared to culture. However, there are insufficient data for these tests to replace culture as a primary means of diagnosis in newborns. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial treatment for chlamydial conjunctivitis should be based upon a positive diagnostic test. By contrast, initial therapy for chlamydial pneumonia should be initiated on a presumptive diagnosis based upon clinical and radiographic findings until diagnostic tests results are available. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There have been few studies examining the optimal treatment for C. trachomatis in the newborn; clinical experience is greatest with macrolides, in particular,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      . The American Academy of Pediatrics (AAP) Committee on Infectious Disease and the Centers for Disease Control (CDC) recommend erythromycin for either chlamydial conjunctivitis or pneumonia. A typical dose of erythromycin is 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day PO in four divided doses for 14 days.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       Azithromycin",
"      </a>",
"      may be used as an alternative to erythromycin. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Choice of antibiotic'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend a course of oral rather than topical",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      for treatment of neonatal C. trachomatis conjunctivitis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Topical therapy is ineffective and not necessary if patient is treated systemically.",
"     </li>",
"     <li>",
"      We suggest a course of oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      for pneumonia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic program that identifies and treats all pregnant women with genital C. trachomatis infection is the most effective way to prevent perinatal chlamydial infection.",
"     </li>",
"     <li>",
"      The currently recommended topical therapies for prevention of neonatal gonococcal conjunctivitis are not effective for preventing chlamydial conjunctivitis. Because of the relatively low risk of clinically significant disease in infants born to mothers with active chlamydial infection and the potential risk of pyloric stenosis with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      therapy, we do NOT recommend administering oral prophylactic antibiotics to asymptomatic infants exposed to maternal C. trachomatis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/1\">",
"      Bell TA, Stamm WE, Kuo CC, et al. Risk of perinatal transmission of Chlamydia trachomatis by mode of delivery. J Infect 1994; 29:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/2\">",
"      Shariat H, Young M, Abedin M. An interesting case presentation: a possible new route for perinatal acquisition of Chlamydia. J Perinatol 1992; 12:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/3\">",
"      Bell TA. Chlamydia trachomatis infection in dizygotic twins delivered by caesarean section. Genitourin Med 1988; 64:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/4\">",
"      M&aring;rdh PA, Johansson PJ, Svenningsen N. Intrauterine lung infection with Chlamydia trachomatis in a premature infant. Acta Paediatr Scand 1984; 73:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/5\">",
"      Givner LB, Rennels MB, Woodward CL, Huang SW. Chlamydia trachomatis infection in infant delivered by cesarean section. Pediatrics 1981; 68:420.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Chlamydia trachomatis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering, LK (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.276.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/7\">",
"      FitzSimmons J, Callahan C, Shanahan B, Jungkind D. Chlamydial infections in pregnancy. J Reprod Med 1986; 31:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/8\">",
"      Much DH, Yeh SY. Prevalence of Chlamydia trachomatis infection in pregnant patients. Public Health Rep 1991; 106:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/9\">",
"      Oakeshott P, Hay P, Hay S, et al. Association between bacterial vaginosis or chlamydial infection and miscarriage before 16 weeks' gestation: prospective community based cohort study. BMJ 2002; 325:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/10\">",
"      Niccolai LM, Ethier KA, Kershaw TS, et al. Pregnant adolescents at risk: sexual behaviors and sexually transmitted disease prevalence. Am J Obstet Gynecol 2003; 188:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/11\">",
"      Schachter J, Grossman M, Sweet RL, et al. Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA 1986; 255:3374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/12\">",
"      Hammerschlag MR, Chandler JW, Alexander ER, et al. Longitudinal studies on chlamydial infections in the first year of life. Pediatr Infect Dis 1982; 1:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/13\">",
"      Frommell GT, Rothenberg R, Wang S, McIntosh K. Chlamydial infection of mothers and their infants. J Pediatr 1979; 95:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/14\">",
"      Hammerschlag MR, Anderka M, Semine DZ, et al. Prospective study of maternal and infantile infection with Chlamydia trachomatis. Pediatrics 1979; 64:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/15\">",
"      Chandler JW, Alexander ER, Pheiffer TA, et al. Ophthalmia neonatorum associated with maternal chlamydial infections. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1977; 83:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/16\">",
"      Heggie AD, Lumicao GG, Stuart LA, Gyves MT. Chlamydia trachomatis infection in mothers and infants. A prospective study. Am J Dis Child 1981; 135:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/17\">",
"      Rosenman MB, Mahon BE, Downs SM, Kleiman MB. Oral erythromycin prophylaxis vs watchful waiting in caring for newborns exposed to Chlamydia trachomatis. Arch Pediatr Adolesc Med 2003; 157:565.",
"     </a>",
"    </li>",
"    <li>",
"     Darville, T. Chlamydia Infctions. In: Infectious Diseases of the Fetus and Newborn Infant, 7, Remington, JS, Klein JO, Wilson, CB, Nizet V, MaldonadoYA (Eds), Elsevier Saunders, Philadelphia 2010. p.600.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/19\">",
"      Mordhorst CH, Dawson C. Sequelae of neonatal inclusion conjunctivitis and associated disease in parents. Am J Ophthalmol 1971; 71:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/20\">",
"      Weinstock H, Dean D, Bolan G. Chlamydia trachomatis infections. Infect Dis Clin North Am 1994; 8:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/21\">",
"      Goscienski PJ, Sexton RR. Follow-up studies in neonatal inclusion conjunctivitis. Am J Dis Child 1972; 124:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/22\">",
"      Forster RK, Dawson CR, Schachter J. Late follow-up of patients with neonatal inclusion conjunctivitis. Am J Ophthalmol 1970; 69:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/23\">",
"      Shinkwin CA, Gibbin KP. Neonatal upper airway obstruction caused by chlamydial rhinitis. J Laryngol Otol 1995; 109:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/24\">",
"      Tipple MA, Beem MO, Saxon EM. Clinical characteristics of the afebrile pneumonia associated with Chlamydia trachomatis infection in infants less than 6 months of age. Pediatrics 1979; 63:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/25\">",
"      Attenburrow AA, Barker CM. Chlamydial pneumonia in the low birthweight neonate. Arch Dis Child 1985; 60:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/26\">",
"      Sollecito D, Midulla M, Bavastrelli M, et al. Chlamydia trachomatis in neonatal respiratory distress of very preterm babies: biphasic clinical picture. Acta Paediatr 1992; 81:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/27\">",
"      Colarizi P, Chiesa C, Pacifico L, et al. Chlamydia trachomatis-associated respiratory disease in the very early neonatal period. Acta Paediatr 1996; 85:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/28\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/29\">",
"      Judson FN. Assessing the number of genital chlamydial infections in the United States. J Reprod Med 1985; 30:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/30\">",
"      Black CM. Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin Microbiol Rev 1997; 10:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/31\">",
"      Darville T. Chlamydia trachomatis infections in neonates and young children. Semin Pediatr Infect Dis 2005; 16:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/32\">",
"      Hammerschlag MR, Roblin PM, Gelling M, et al. Use of polymerase chain reaction for the detection of Chlamydia trachomatis in ocular and nasopharyngeal specimens from infants with conjunctivitis. Pediatr Infect Dis J 1997; 16:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/33\">",
"      Yip PP, Chan WH, Yip KT, et al. The use of polymerase chain reaction assay versus conventional methods in detecting neonatal chlamydial conjunctivitis. J Pediatr Ophthalmol Strabismus 2008; 45:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/34\">",
"      Centers for, Disease Control, and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR Recomm Rep 2010; 59:RR12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/35\">",
"      Heggie AD, Jaffe AC, Stuart LA, et al. Topical sulfacetamide vs oral erythromycin for neonatal chlamydial conjunctivitis. Am J Dis Child 1985; 139:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/36\">",
"      Hammerschlag MR, Gelling M, Roblin PM, et al. Treatment of neonatal chlamydial conjunctivitis with azithromycin. Pediatr Infect Dis J 1998; 17:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/37\">",
"      Rours IG, Hammerschlag MR, Ott A, et al. Chlamydia trachomatis as a cause of neonatal conjunctivitis in Dutch infants. Pediatrics 2008; 121:e321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/38\">",
"      Wu SX, Yang J, Liu G. A clinical study in China of neonatal conjunctivitis caused by Chlamydia trachomatis. Clin Pediatr (Phila) 2003; 42:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/39\">",
"      Jain S. Perinatally acquired Chlamydia trachomatis associated morbidity in young infants. J Matern Fetal Med 1999; 8:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/40\">",
"      Rours GI, Hammerschlag MR, Van Doornum GJ, et al. Chlamydia trachomatis respiratory infection in Dutch infants. Arch Dis Child 2009; 94:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/41\">",
"      Hammerschlag MR, Cummings C, Roblin PM, et al. Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. N Engl J Med 1989; 320:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/42\">",
"      Koumans EH, Rosen J, van Dyke MK, et al. Prevention of mother-to-child transmission of infections during pregnancy: implementation of recommended interventions, United States, 2003-2004. Am J Obstet Gynecol 2012; 206:158.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/43\">",
"      Chen JY. Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatr Infect Dis J 1992; 11:1026.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Gonococcal infections. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering, LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p. 301.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/45\">",
"      Bell TA, Sandstr&ouml;m KI, Gravett MG, et al. Comparison of ophthalmic silver nitrate solution and erythromycin ointment for prevention of natally acquired Chlamydia trachomatis. Sex Transm Dis 1987; 14:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/46\">",
"      Isenberg SJ, Apt L, Wood M. A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. N Engl J Med 1995; 332:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27992/abstract/47\">",
"      Chang K, Cheng VY, Kwong NS. Neonatal haemorrhagic conjunctivitis: a specific sign of chlamydial infection. Hong Kong Med J 2006; 12:27.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4993 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27992=[""].join("\n");
var outline_f27_21_27992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk of transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Indications for testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Specimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diagnostic methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nucleic acid amplification tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Antigen detection methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Choice of antibiotic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Risk of pyloric stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment of the mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Maternal screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prophylaxis against conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4993\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4993|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/46/4839\" title=\"picture 1\">",
"      Neonatal chlamydia conjunctivitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=related_link\">",
"      Gonococcal infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=related_link\">",
"      Infantile hypertrophic pyloric stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=related_link\">",
"      Management of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=related_link\">",
"      Overview of the routine management of the healthy newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/34/3618?source=related_link\">",
"      Patient information: Newborn conjunctivitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) species in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=related_link\">",
"      Screening for Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_21_27993="Overview of hand infections";
var content_f27_21_27993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hand infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27993/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27993/contributors\">",
"     Shimpei Ono, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27993/contributors\">",
"     Sandeep Sebastin, MMed, FAMS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27993/contributors\">",
"     Kevin C Chung, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27993/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27993/contributors\">",
"     Charles E Butler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27993/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27993/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/21/27993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27990826\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections of the upper limb are common and account for up to 35 percent of patients admitted to a hand surgery service. The majority of patients with acute hand infections are healthy and active young adults who have neglected or delayed appropriate treatment for minor trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/1\">",
"     1",
"    </a>",
"    ]. More severe infections with significant morbidity are seen in patients with impaired immune status.",
"   </p>",
"   <p>",
"    Early and superficial infections of the hand may respond to nonsurgical management; however, most hand infections are surgical emergencies. Prompt evaluation and proper treatment of hand infections can mean the difference between an excellent outcome and permanent disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H986789529\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation and management of a hand infection includes a focused history and examination, and often involves laboratory evaluation and imaging. The area of erythema should be marked to help document progression of the infection. Elevation of the hand and arm and application of a heat pack, along with appropriate pain control, will decrease swelling and provide comfort. Empiric antibiotics should be started. These measures are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H986789489\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A focused medical history should determine the possible source of infection, progress of the infection, the immune status of the patient, and any relevant past medical history:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Symptoms ",
"      </strong>",
"      The onset of pain, loss of function, fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chills, and any spontaneous drainage should be documented. Severe throbbing pain is suggestive of an abscess in a confined space. A rapid deterioration in general condition is suggestive of severe infections like necrotizing fasciitis and gas gangrene. (See",
"      <a class=\"local\" href=\"#H1281559541\">",
"       'Necrotizing fasciitis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"       \"Necrotizing soft tissue infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Prior injury",
"      </strong>",
"       Any prior hand injury from splinters, bites, needle sticks, or as a result of attempts at drainage by the patient or other clinicians should be noted.",
"     </li>",
"     <li>",
"      <strong>",
"       Hand dominance ",
"      </strong>",
"      The patient&rsquo;s dominant hand should be documented.",
"     </li>",
"     <li>",
"      <strong>",
"       Occupation",
"      </strong>",
"       The patient&rsquo;s occupation may increase his or her exposure to certain infectious agents. As an example, dishwashers are more prone to chronic paronychia.",
"     </li>",
"     <li>",
"      <strong>",
"       Immune status",
"      </strong>",
"       Host factors that lower immune status increase the risk of significant morbidity from hand infections.",
"     </li>",
"     <li>",
"      <strong>",
"       Tetanus prophylaxis",
"      </strong>",
"       Tetanus toxoid immunization should be administered to those who have completed the primary series of immunization but who received a booster immunization more than five years previously (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 1",
"      </a>",
"      ). Tetanus toxoid (0.5 mL intramuscularly) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"       tetanus immune globulin",
"      </a>",
"      (250 units intramuscularly) should be given to patients who have received less than three doses of tetanus toxoid or whose immunization status is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link&amp;anchor=H7#H7\">",
"       \"Tetanus-diphtheria toxoid vaccination in adults\", section on 'Immunization for patients with injuries'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Inflammatory arthropathies",
"      </strong>",
"       Patients should be questioned about any similar episodes in the past and whether they were ever treated for inflammatory arthropathies like rheumatoid arthritis and gout. This medical history combined with clinical examination and investigations can help with the difficult differentiation between an infectious and an inflammatory process. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25879?source=see_link\">",
"       \"Evaluation of the patient with hand pain\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27990920\">",
"    <span class=\"h2\">",
"     Clinical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vital signs should be recorded. The",
"    <strong>",
"     entire",
"    </strong>",
"    upper extremity should be exposed for a systematic examination. The hand and wrist are examined for the presence of swelling, deformity, open wounds, alignment of the fingers, neurovascular status, and local tenderness. The following findings should be noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Inflammation",
"      </strong>",
"      ",
"      <strong>",
"      </strong>",
"      Erythema may indicate the presence of cellulitis, lymphangitis, or an underlying abscess. The location of any swelling can provide clues about the anatomical location of a deep infection.",
"     </li>",
"     <li>",
"      <strong>",
"       Fluctuance ",
"      </strong>",
"      Fluctuance indicates an",
"      <strong>",
"      </strong>",
"      underlying abscess (",
"      <a class=\"graphic graphic_picture graphicRef73140 \" href=\"UTD.htm?9/4/9286\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Skin necrosis",
"      </strong>",
"       Discoloration of the skin over an abscess indicates pressure necrosis and impending rupture. Central skin necrosis with surrounding erythema (dermonecrosis) is a feature of methicillin-resistant Staphylococcus aureus (MRSA) infections (",
"      <a class=\"graphic graphic_picture graphicRef52190 \" href=\"UTD.htm?16/54/17253\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Crepitus",
"      </strong>",
"       Subcutaneous crepitus is associated with gas gangrene. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link&amp;anchor=H3#H3\">",
"       \"Clostridial myonecrosis\", section on 'Traumatic gas gangrene'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Adenopathy ",
"      </strong>",
"      Epitrochlear and axillary lymphadenopathy often accompany an infection of the forearm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link&amp;anchor=H3#H3\">",
"       \"Evaluation of peripheral lymphadenopathy in adults\", section on 'Localized lymphadenopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tenderness and limited movement",
"      </strong>",
"       Fusiform swelling of the whole finger, partially flexed posture of the finger, tenderness limited to the course of the flexor tendon sheath, and disproportionate pain on passive extension of the finger indicate the presence of a deep infection of the synovial space. These are referred to as the &ldquo;Kanavel&rdquo; signs. (See",
"      <a class=\"local\" href=\"#H27991357\">",
"       'Synovial space infections'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27990955\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical examination is the mainstay of diagnosis of the vast majority of hand infections. In patients that are systemically ill or immunocompromised, laboratory studies such as complete blood count may serve as a useful baseline. Other studies (eg, renal function, liver function) should be ordered based upon the patient&rsquo;s underlying medical conditions. Blood cultures should be obtained for febrile or septic patients. For patients with an open or draining wound, a sample of the drainage should be sent for Gram stain, aerobic, and anaerobic culture. For patients with an area of fluctuance, the abscess should be aspirated, and the aspirate should be sent for Gram stain and culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11494?source=see_link\">",
"     \"Blood cultures for the detection of bacteremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34791?source=see_link\">",
"     \"Approach to Gram stain and culture results in the microbiology laboratory\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27990962\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1455120627\">",
"    <span class=\"h3\">",
"     Plain films",
"    </span>",
"    &nbsp;&mdash;&nbsp;A radiograph of the affected part should be obtained when indicated by clinical findings and history to evaluate for the following conditions, and as a baseline for future comparison:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Foreign bodies",
"      </strong>",
"       A foreign body can serve as a nidus of infection and requires removal for an infection to resolve (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66000 \" href=\"UTD.htm?11/21/11600\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Fracture",
"      </strong>",
"       The type of radiograph depends on the clinical assessment and suspected injuries, based on the physical examination and mechanism of injury. Consultation with a radiologist is helpful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/61/18393?source=see_link&amp;anchor=H28605137#H28605137\">",
"       \"Overview of finger, hand, and wrist fractures\", section on 'Radiographic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Periosteal elevation",
"      </strong>",
"       Periosteal elevation is a nonspecific reaction to tumor, infection, trauma, certain",
"      <sup>",
"      </sup>",
"      drugs, and some arthritic conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Gas in the soft tissues",
"      </strong>",
"       Gas in soft tissue is seen in type I necrotizing fasciitis or gas gangrene caused by clostridia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link\">",
"       \"Clostridial myonecrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Osteomyelitis",
"      </strong>",
"       Radiographs may suggest a diagnosis of osteomyelitis. However, imaging findings may be subtle or radiographically absent in the first one to two weeks of infection. Imaging of suspected osteomyelitis is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"       \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Septic arthritis",
"      </strong>",
"       In the early phase of septic arthritis, the radiographs will show widening of the joint space and surrounding soft tissue swelling. A MRI scan is useful in demonstrating joint effusion and can identify areas of bone involvement or soft tissue abscess. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link&amp;anchor=H10#H10\">",
"       \"Septic arthritis in adults\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1455120608\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a deep abscess is suspected, an ultrasound examination should be performed for confirmation and to look for fluid collections along the tendon sheaths [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27991357\">",
"     'Synovial space infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281559432\">",
"    <span class=\"h2\">",
"     Outline the area of erythema",
"    </span>",
"    &nbsp;&mdash;&nbsp;The area of erythema should be outlined with an indelible marker (",
"    <a class=\"graphic graphic_picture graphicRef63361 \" href=\"UTD.htm?34/14/35042\">",
"     picture 3",
"    </a>",
"    ). This will allow assessment of progression or regression of the infectious process and is extremely valuable in necrotizing fasciitis, where the erythema will progress significantly in a couple of hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281559441\">",
"    <span class=\"h2\">",
"     Splinting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splint immobilization protects the affected area, limits opening of tissue planes restricting the spread of infection, and decreases pain. Splinting in a position of function can help protect against flexion contractures, reduce stiffness, and hasten rehabilitation (",
"    <a class=\"graphic graphic_picture graphicRef77837 \" href=\"UTD.htm?35/21/36177\">",
"     picture 4",
"    </a>",
"    ). If a single digit is infected, a finger splint supporting the interphalangeal joints in extension is usually adequate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/61/18393?source=see_link&amp;anchor=H10043308#H10043308\">",
"     \"Overview of finger, hand, and wrist fractures\", section on 'Splinting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281559450\">",
"    <span class=\"h2\">",
"     Elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevation helps to reduce edema by improving venous and lymphatic drainage. The goal of elevation is to keep the hand above the level of the heart so that dependent drainage can occur. To accomplish appropriate elevation, patients should be counseled to rest with the extremity above their chest using pillows or commercially available supports while sitting and lying down. The usual arm slings do",
"    <strong>",
"     not",
"    </strong>",
"    provide adequate elevation (",
"    <a class=\"graphic graphic_picture graphicRef54790 \" href=\"UTD.htm?35/62/36833\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281559459\">",
"    <span class=\"h2\">",
"     Heat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Application of heat increases the delivery of inflammatory cells to the affected area by local vasodilatation, may enhance antibiotic delivery to the tissue, and improves patient comfort. Moist heat is more effective than dry heat. Warm soaks reach maximum vasodilatory effect in approximately 10 minutes. Short frequent soaks are preferred over continuous immersion. For more severe infections for which soaks are inadvisable, the affected part can be wrapped in moist hot towels and then covered with plastic wrap to create a vapor barrier, with a dry towel to insulate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281559424\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy is an indispensable adjunct to surgical management. In general, initial empiric antibiotic therapy is selected based on epidemiologic clues for likely pathogen(s) as well as the Gram stain; the result of culture and sensitivity testing takes two to three days. Empiric antibiotic therapy should cover skin flora (including Staphylococcus aureus and beta-hemolytic streptococci); first generation cephalosporins provide appropriate coverage for these organisms. Issues related to coverage for methicillin resistant S. aureus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the above coverage, empiric anaerobic coverage is also warranted in the setting of bite wounds, as discussed in the following sections (",
"    <a class=\"graphic graphic_table graphicRef73450 \" href=\"UTD.htm?14/18/14637\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link\">",
"     \"Soft tissue infections due to human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168815709\">",
"    <span class=\"h1\">",
"     BITE WOUNDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281559770\">",
"    <span class=\"h2\">",
"     Animal bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although dogs are responsible for the vast majority of animal bites, cat bites are responsible for the majority of infected bites (76 percent). Cat bites often result in multiple small puncture wounds and are likely to cause infection because cats have sharp teeth that inoculate bacteria deeply in the tissue (",
"    <a class=\"graphic graphic_picture graphicRef55434 \" href=\"UTD.htm?39/24/40325\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Aerobic and anaerobic cultures of bite wounds should be obtained. The rabies immunization status of the animal should be documented (if known). Cat owners should be asked if their cat hunts and eats wild animals. Such cats are at risk of carrying Francisella tularensis, which can cause tularemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=see_link\">",
"     \"When to use rabies prophylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Animal bites should be opened and irrigated as soon as possible. Patients with superficial wounds who are evaluated within a few hours of the injury can be treated under local anesthesia. Patients who present later or have evidence of infection in a deeper tissue plane should undergo debridement and irrigation of the wounds in the operating room. The management of animal bites is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281559777\">",
"    <span class=\"h2\">",
"     Human bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human bites are serious injuries because of the virulence of the human oral flora [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The most common human bite injury to the hand is clenched fist injury also known as a &ldquo;fight-bite&rdquo;, from striking another person's mouth. These injuries can be missed in the emergency department because patients may be reluctant to provide an accurate account of the injury and the wound appears innocuous. Fight-bite injuries to the hand usually occur with the fist in a clenched position. When the fist makes contact with a victim's mouth,&nbsp;the teeth can&nbsp;easily penetrate the skin and extensor tendon that are stretched tightly over the metacarpal head, thus&nbsp;injuring the underlying bone and joint and resulting in an open metacarpal head fracture, which may progress to septic arthritis (",
"    <a class=\"graphic graphic_figure graphicRef67311 \" href=\"UTD.htm?17/4/17475\">",
"     figure 1",
"    </a>",
"    ). Patients with fight-bites present with a lack of normal active extension of the involved joint (extension lag), pain, swelling, and erythema. Purulent drainage from the wound may also be seen. When a patient with a fight-bite injury is examined with his or her fingers extended, the small skin laceration may no longer correspond to the fracture site and is frequently overlooked (",
"    <a class=\"graphic graphic_picture graphicRef69232 \" href=\"UTD.htm?11/36/11845\">",
"     picture 7",
"    </a>",
"    ). A radiograph (Brewerton view) should be obtained to look for a fracture of the metacarpal head, retained foreign body (tooth fragment), or osteomyelitis in a delayed presentation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77588 \" href=\"UTD.htm?8/63/9202\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22707?source=see_link\">",
"     \"Metacarpal head fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Human bite injuries require hospital admission, antibiotics, debridement in the OR, and delayed primary wound closure. Wide exposure of the wound is required and the joint should be opened and inspected, even if the joint capsule appears intact (",
"    <a class=\"graphic graphic_picture graphicRef80342 \" href=\"UTD.htm?28/44/29381\">",
"     picture 8",
"    </a>",
"    ). After cleansing and debridement, the wound should be left open with a drain. Tendon repair and skin closure are delayed until the infection has been eradicated. If the clinical symptoms do not improve, radiographs should be repeated and compared with initial radiographs to rule out osteomyelitis. The management of infections from human bites is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link\">",
"     \"Soft tissue infections due to human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27990999\">",
"    <span class=\"h1\">",
"     SUPERFICIAL HAND INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial hand infections arise from the skin and subcutaneous tissue in a plane superficial to the tendons. These include cellulitis, lymphangitis, paronychia, pulp space infections, herpetic whitlow, subcutaneous abscess, and web space abscess. As a superficial hand infection progresses, it follows the path of least resistance and may involve deeper tissue planes. (See",
"    <a class=\"local\" href=\"#H27991348\">",
"     'Deep infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991008\">",
"    <span class=\"h2\">",
"     Cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis is a diffuse infection of the subcutaneous tissue without pus formation, which is",
"    <strong>",
"    </strong>",
"    characterized by a warm, tender area of erythema and edema that is well demarcated and progresses over time (",
"    <a class=\"graphic graphic_picture graphicRef62491 \" href=\"UTD.htm?3/2/3107\">",
"     picture 9",
"    </a>",
"    ). The movements of any underlying joints are painful and restricted. A patient with cellulitis of the hand requires hospital admission for rest, elevation, warm soaks, antibiotics, and close monitoring. If there is no response to antibiotic therapy (indicated by improvement in patient symptoms and regression of area of erythema), pus formation or a more serious deep hand infection is likely. The diagnosis and treatment of cellulitis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1299985513\">",
"    <span class=\"h2\">",
"     Lymphangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphangitis of the hand or arm is an infection of the lymphatics, and the presentation is similar to cellulitis. However, unlike cellulitis, it has a distal nidus, erythematous streaks that spread proximally up the arm, and is non-pus forming (",
"    <a class=\"graphic graphic_picture graphicRef76356 \" href=\"UTD.htm?35/41/36497\">",
"     picture 10",
"    </a>",
"    ). There may be associated palpable tender epitrochlear or axillary lymphadenopathy. A patient with lymphangitis requires hospital admission for rest, elevation, warm soaks, antibiotics, and close monitoring. If there is no response to antibiotic therapy, the diagnosis may not be lymphangitis, and a more serious deep hand infection is likely. The diagnosis and treatment of lymphangitis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11942?source=see_link\">",
"     \"Lymphangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991094\">",
"    <span class=\"h2\">",
"     Paronychia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute paronychia is a bacterial infection of the lateral nail fold characterized by erythema, swelling, and tenderness along the nail fold, especially in the dorsolateral corner (",
"    <a class=\"graphic graphic_picture graphicRef55415 \" href=\"UTD.htm?36/44/37571\">",
"     picture 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Acute eponychia is an infection of the proximal nail fold (",
"    <a class=\"graphic graphic_picture graphicRef69216 \" href=\"UTD.htm?39/20/40260\">",
"     picture 12",
"    </a>",
"    ). Chronic paronychia is a fungal infection of the nail fold (",
"    <a class=\"graphic graphic_picture graphicRef79796 \" href=\"UTD.htm?22/20/22851\">",
"     picture 13",
"    </a>",
"    ). If left untreated, an abscess can develop between the nail plate, gradually progressing to involve the proximal and then the opposite lateral nail fold. The nail plate may be lifted up and in some cases the infection can extend to the pulp space. Nonsurgical treatment of acute paronychia and acute eponychia is appropriate in patients who present early without an abscess and consists of oral antibiotics, warm soaks, rest, and elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/8\">",
"     8",
"    </a>",
"    ]. Surgical drainage is indicated in patients who present late and have an abscess cavity (",
"    <a class=\"graphic graphic_figure graphicRef57429 \" href=\"UTD.htm?16/7/16498\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67097 \" href=\"UTD.htm?27/44/28353\">",
"     figure 3",
"    </a>",
"    ). The diagnosis and treatment of paronychia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37846?source=see_link&amp;anchor=H4#H4\">",
"     \"Paronychia and ingrown toenails\", section on 'Acute paronychia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991150\">",
"    <span class=\"h2\">",
"     Pulp space infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The digital pulp, the fleshy mass at the finger tips, is divided into multiple compartments by fibrous septae that provide structural support (",
"    <a class=\"graphic graphic_figure graphicRef80567 \" href=\"UTD.htm?30/20/31049\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Pulp abscesses account for 15 to 20 percent of all hand infections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/9\">",
"     9",
"    </a>",
"    ], and the thumb and index finger are the most commonly affected digits [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/10\">",
"     10",
"    </a>",
"    ]. A severe infection or abscess of the pulp space, called a felon, results in increased pressure and can lead to ischemic necrosis of surrounding tissue, osteomyelitis, flexor tenosynovitis, or septic arthritis of the distal interphalangeal joint (DIPJ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/11\">",
"     11",
"    </a>",
"    ]. A pulp abscess usually occurs after a puncture wound but may also result from untreated acute paronychia.",
"   </p>",
"   <p>",
"    Patients with pulp space infections present with pain, cellulitis, and an associated tender fluctuant swelling. The pain is severe and throbbing, worsens in the dependent position, and usually does not allow the patient to sleep. The swelling is limited to the DIPJ and an area of imminent rupture (pointing) may be obvious (",
"    <a class=\"graphic graphic_figure graphicRef80567 \" href=\"UTD.htm?30/20/31049\">",
"     figure 4",
"    </a>",
"    ). Occasionally the abscess may spontaneously discharge through the skin, decompressing it and thus reducing symptoms. A radiograph should be obtained to look for any retained foreign bodies and rule out involvement of the distal phalanx or the DIPJ.",
"   </p>",
"   <p>",
"    A very early presentation of a pulp space infection without a fluctuant swelling may be treated with warm soaks, rest, elevation, and oral antibiotics. However, most patients with a pulp abscess require surgical intervention. A simple incision and drainage procedure may provide temporary relief; however, it is better to debride the abscess cavity in the operating room because the infection may be more extensive than the symptoms and clinical appearance suggest (",
"    <a class=\"graphic graphic_figure graphicRef59879 \" href=\"UTD.htm?32/30/33255\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991206\">",
"    <span class=\"h2\">",
"     Herpetic whitlow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpetic whitlow is a viral infection of the hand caused by inoculation of herpes simplex virus (HSV) into broken skin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Patients with herpetic whitlow usually present with tingling and burning pain of the hand that is disproportionate to the clinical findings associated with influenza-like symptoms, including fever, lymphadenitis, epitrochlear, and axillary lymphadenopathy. This is followed by the development of erythema, swelling, and 1 to 2 mm vesicles containing clear fluid (",
"    <a class=\"graphic graphic_picture graphicRef71643 \" href=\"UTD.htm?31/59/32690\">",
"     picture 14",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52029 \" href=\"UTD.htm?9/30/9696\">",
"     picture 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75510 \" href=\"UTD.htm?30/31/31231\">",
"     picture 16",
"    </a>",
"    ), which coalesce to form larger blisters. The blister fluid is initially clear but becomes turbid and appears purulent, mimicking a bacterial infection. However, unlike a bacterial infection, the pulp space is soft and not tense. The condition usually resolves in two to three weeks but can recur.",
"   </p>",
"   <p>",
"    The treatment of herpetic whitlow is conservative (rest, elevation, and antiinflammatory agents). Herpetic whitlow is a self-limiting condition. A dry dressing is used to cover the digit to prevent transmission of the infection. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    has not been shown to be effective in treatment. Surgery is contraindicated because it will spread the infection into healthy tissue and may result in secondary bacterial infection. Oral or intravenous acyclovir is recommended only for immunocompromised patients or those with severe infections. Herpetic whitlow does not require use of antibiotics unless a secondary",
"    <strong>",
"    </strong>",
"    bacterial infection is suspected. A Tzanck smear is useful in early diagnosis as it is quick and relatively inexpensive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H12#H12\">",
"     \"Dermatologic procedures\", section on 'Tzanck smear'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Herpetic whitlow usually affects only one finger and is often confused with acute paronychia or a pulp abscess. Other viruses can also cause vesicles on the hand. As an example, a Coxsackie virus infection (enterovirus) should be suspected if multiple fingers are affected.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Hand, foot, and mouth syndrome'",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991248\">",
"    <span class=\"h2\">",
"     Subcutaneous abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subcutaneous abscess of the fingers or hand is usually the result of minor penetrating trauma that was neglected.",
"   </p>",
"   <p>",
"    A subcutaneous abscess of the",
"    <strong>",
"    </strong>",
"    finger presents with localized swelling, erythema, and restricted motion at the adjacent joints (",
"    <a class=\"graphic graphic_picture graphicRef60421 \" href=\"UTD.htm?6/61/7126\">",
"     picture 17",
"    </a>",
"    ). The digit is usually in a flexed posture, and there may be evidence of an inflamed puncture wound from a penetrating injury. In late presentations, the abscess may be pointing or discharging through a sinus.",
"   </p>",
"   <p>",
"    Subcutaneous abscesses of the hand can occur on either the palmar or dorsal aspects of the hand:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abscesses of the palmar skin are typically localized because the fibrous septae anchoring palmar skin limit the spread of infection (",
"      <a class=\"graphic graphic_picture graphicRef74144 \" href=\"UTD.htm?9/14/9444\">",
"       picture 18",
"      </a>",
"      ). A subcutaneous abscess of the palm presents with erythema and mild swelling on both the palmar and dorsal aspects of the hand. Palpation of the tendon sheath proximal and distal to a palmar subcutaneous abscess will help differentiate it from pyogenic flexor tenosynovitis that is confined along the path of the tendon sheath.",
"     </li>",
"     <li>",
"      In contrast, the dorsal skin of the hand is loosely anchored to the underlying tissue, which allows the spread of infection into two potential spaces: the dorsal subcutaneous space, which is superficial to the extensor tendons, and the dorsal subaponeurotic space, which is deep to the extensor tendons (",
"      <a class=\"graphic graphic_figure graphicRef79227 \" href=\"UTD.htm?17/14/17639\">",
"       figure 6",
"      </a>",
"      ). A subcutaneous abscess of the dorsum of the hand is associated with significant dorsal hand swelling, a tender fluctuant mass, and pain with extension of the fingers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aspiration of the abscess will provide decompression and reduce pain in the period before a formal surgical debridement can be performed. Patients who require extensive debridement for dorsal abscesses may need additional surgical procedures to resurface the resulting soft tissue defect (",
"    <a class=\"graphic graphic_picture graphicRef53109 \" href=\"UTD.htm?18/6/18535\">",
"     picture 19",
"    </a>",
"    ). A radiograph should be obtained to look for any retained foreign bodies and rule out involvement of the bone or joints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991298\">",
"    <span class=\"h2\">",
"     Web space abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;An interdigital web space infection is a subcutaneous abscess involving the web space where the infection may be present on the palmar and dorsal aspects simultaneously. It is also known as a collar button abscess because of its resemblance to buttons used on dress shirts in the early nineteenth century. A web space abscess usually results from a penetrating injury or a fissure in the web space. It may also result from infection of a palmar callus in manual laborers or spread from an adjacent palmar subcutaneous abscess. The infection begins in the palmar subcutaneous portion of the web space and then spreads dorsally over the superficial transverse metacarpal ligament to involve the dorsal subcutaneous space.",
"   </p>",
"   <p>",
"    A patient with a web space abscess presents with pain and swelling limited to the web space and distal palm. There may be greater swelling on the dorsal aspect of the web, although the primary focus of infection is on the palmar side. The adjacent fingers are usually in an abducted position, and this may help differentiate it from a pure dorsal or palmar subcutaneous abscess, where the fingers are in the normal adducted position. A web space abscess requires a combined palmar and dorsal surgical approach for adequate drainage and debridement (",
"    <a class=\"graphic graphic_figure graphicRef62829 \" href=\"UTD.htm?12/49/13072\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991348\">",
"    <span class=\"h1\">",
"     DEEP INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep hand infections are deep to the tendon sheaths and include synovial space infections, deep fascial space infections, septic arthritis, and necrotizing fasciitis. In the early stage, the infection is limited by the compartmentalized anatomy of the hand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991357\">",
"    <span class=\"h2\">",
"     Synovial space infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flexor tendons of the hand are enclosed in a double-layered synovial sheath composed of an inner visceral layer and an outer parietal layer, which create a closed system (",
"    <a class=\"graphic graphic_figure graphicRef70488 \" href=\"UTD.htm?19/63/20470\">",
"     figure 8",
"    </a>",
"    ). The synovial spaces intercommunicate and provide an optimal environment for bacterial growth because they are poorly vascularized and rich in synovial fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Bacterial proliferation within the synovial sheath rapidly destroys the tendon&rsquo;s gliding mechanism and leads to increased pressure within the sheath which obstructs the blood flow and causes tendon necrosis and rupture. The infection can spread from the bursa into the surrounding soft tissue compartments. The infection can also track from the radial to the ulnar bursa and vice versa to form a so-called horseshoe abscess.",
"   </p>",
"   <p>",
"    Patients with an isolated infection of the digital flexor sheaths (pyogenic flexor tenosynovitis) typically present with fusiform swelling of the whole finger, partially flexed posture of the finger, tenderness limited to the course of the flexor tendon sheath, and disproportionate pain on passive extension of the finger (Kanavel signs), although all signs may not be seen in an early presentation (",
"    <a class=\"graphic graphic_picture graphicRef51632 \" href=\"UTD.htm?28/63/29685\">",
"     picture 20",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients with an infection of the radial bursa, ulnar bursa, space of Parona, or a combination of these (horseshoe abscess) present with a flexed attitude of the wrist, swelling, and tenderness along the thenar, hypothenar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the distal wrist crease because of the associated thumb",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    small finger flexor tenosynovitis.",
"   </p>",
"   <p>",
"    In general, the management of tenosynovitis requires surgical intervention and antibiotic therapy (",
"    <a class=\"graphic graphic_picture graphicRef63419 \" href=\"UTD.htm?43/46/44772\">",
"     picture 21",
"    </a>",
"    ). Synovial space infections are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20550?source=see_link\">",
"     \"Infectious tenosynovitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991413\">",
"    <span class=\"h2\">",
"     Deep fascial space infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The palm has three potential closed spaces with well defined anatomical borders: the thenar, midpalmar, and the hypothenar space (",
"    <a class=\"graphic graphic_figure graphicRef77205 \" href=\"UTD.htm?29/10/29863\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These spaces are deep to the flexor tendons but superficial to the interosseous muscles. Infections in these spaces occur following a penetrating injury in most cases and occasionally as an extension from a subcutaneous abscess or adjacent pyogenic flexor tenosynovitis.",
"   </p>",
"   <p>",
"    All deep palmar space infections have palmar swelling and tenderness over the involved palmar space and generalized dorsal swelling:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thenar space abscess is characterized by a widely abducted thumb and fullness on the dorsum of the first web space, with severe pain on adduction or opposition of the thumb (",
"      <a class=\"graphic graphic_picture graphicRef56271 \" href=\"UTD.htm?27/28/28099\">",
"       picture 22",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A midpalmar space abscess is characterized by loss of the normal palmar concavity (",
"      <a class=\"graphic graphic_picture graphicRef66269 \" href=\"UTD.htm?5/41/5782\">",
"       picture 23",
"      </a>",
"      ). The long and ring fingers assume a partially flexed posture, and there is pain on passive extension of these fingers.",
"     </li>",
"     <li>",
"      Hypothenar space infections have much less palmar and dorsal swelling than thenar or midpalmar space infections. In addition, there is no involvement of the fingers or the flexor tendons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis for deep fascial space infections includes pyogenic flexor tenosynovitis, radial or ulnar bursal infections, and subcutaneous abscess. An ultrasound examination can help in determining the location of the abscess cavity and thus differentiate between these conditions. &nbsp;Radiographs are useful to evaluate for a retained foreign body. An ultrasound scan is useful in confirming the presence and location of an abscess cavity.",
"   </p>",
"   <p>",
"    Deep fascial space infections are surgical emergencies, and there is no role for nonoperative treatment. The surgical approaches to thenar space, midpalmar space, and hypothenar space infections are illustrated in the figures (",
"    <a class=\"graphic graphic_figure graphicRef78024 \" href=\"UTD.htm?8/0/8193\">",
"     figure 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55033 \" href=\"UTD.htm?0/17/278\">",
"     figure 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66822 \" href=\"UTD.htm?39/46/40687\">",
"     figure 12",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991462\">",
"    <span class=\"h2\">",
"     Septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic arthritis usually refers to bacterial infection in a joint but also includes fungal and mycobacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Patients with septic arthritis present with a red, swollen, warm, and tender joint that is painful on passive motion. The differential diagnosis of bacterial arthritis includes gout, pseudogout, arthritis, and Lyme disease, each of which can present with acute involvement of one or a few joints (",
"    <a class=\"graphic graphic_table graphicRef62597 \" href=\"UTD.htm?38/30/39404\">",
"     table 3",
"    </a>",
"    ).",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Treatment of acute bacterial arthritis requires appropriate antimicrobials and adequate joint drainage (",
"    <a class=\"graphic graphic_algorithm graphicRef77858 \" href=\"UTD.htm?22/55/23422\">",
"     algorithm 1",
"    </a>",
"    ). All septic joints must be explored early to avoid joint damage from the disease process (",
"    <a class=\"graphic graphic_picture graphicRef80113 \" href=\"UTD.htm?8/22/8552\">",
"     picture 24",
"    </a>",
"    ). The diagnosis and treatment of septic arthritis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281559541\">",
"    <span class=\"h2\">",
"     Necrotizing fasciitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing fasciitis is a rapidly progressing, life threatening soft tissue infection caused by a toxin producing bacterium, characterized by widespread fascial necrosis and relative sparing of underlying muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27993/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. These patients feel much worse than suggested by their clinical appearance and may demonstrate systemic signs of sepsis including fever, dehydration, hypotension, and electrolyte imbalance.",
"   </p>",
"   <p>",
"    It is important to differentiate cellulitis from necrotizing fasciitis because the early presentation of both these conditions is similar. However, while the management of cellulitis is conservative, necrotizing fasciitis requires emergency surgical intervention. If necrotizing fasciitis is suspected, an experienced surgeon with critical care expertise should be consulted promptly to manage the patient&rsquo;s care. Surgical treatment consists of wide debridement of skin, subcutaneous tissue, fascia, and any necrotic muscle. The initial debridement is the most important and determines the outcome of treatment (",
"    <a class=\"graphic graphic_picture graphicRef62231 \" href=\"UTD.htm?6/5/6233\">",
"     picture 25",
"    </a>",
"    ). The diagnosis and treatment of necrotizing fasciitis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link&amp;anchor=H8#H8\">",
"     \"Necrotizing soft tissue infections\", section on 'Necrotizing fasciitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168815239\">",
"    <span class=\"h1\">",
"     MYCOBACTERIAL INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon, both typical and atypical mycobacterial infections should be considered in the differential diagnosis of hand infections that are refractory to treatment. As an example, a person employed in a tropical fish aquarium is more likely to develop a mycobacterium marinum infection after a hand injury because this organism is found in warm brackish waters. Because mycobacteria are difficult to culture, a tissue biopsy should be obtained if the diagnosis is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21034?source=see_link\">",
"     \"Cutaneous manifestations of tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link&amp;anchor=H18#H18\">",
"     \"Soft tissue infections following water exposure\", section on 'Mycobacterium marinum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991646\">",
"    <span class=\"h1\">",
"     MIMICKERS OF ACUTE HAND INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of inflammatory conditions of the hand may be wrongly diagnosed as an acute infection of the hand. Some of the common conditions that mimic acute hand infections include gout, pseudogout, acute calcific tendinitis, retained foreign bodies, chemotherapeutic infiltration, pyoderma gangrenosum, metastatic tumor, and factitious illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991653\">",
"    <span class=\"h2\">",
"     Gout",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gout is a disorder of urate metabolism that leads to high levels of uric acid and the formation of urate crystals. Urate crystals can be deposited under the skin, in joints, and within tendon sheaths as &ldquo;gouty tophi&rdquo;, which cause an intense inflammatory process. Inflamed gouty tophi may be mistaken for a felon, a subcutaneous abscess pyogenic flexor tenosynovitis, or septic arthritis (",
"    <a class=\"graphic graphic_picture graphicRef74050 \" href=\"UTD.htm?22/22/22885\">",
"     picture 26",
"    </a>",
"    ). If gout is suspected, serum uric acid values and a radiograph should be obtained. The differentiation between gout and septic arthritis depends on the patient's history, the presence of pre-existing underlying diseases, and the clinical presentation. (See",
"    <a class=\"local\" href=\"#H27991462\">",
"     'Septic arthritis'",
"    </a>",
"    above.) Gout is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991660\">",
"    <span class=\"h2\">",
"     Pseudogout",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudogout (calcium pyrophosphate deposition) is similar to gout except that it is caused by deposition of calcium pyrophosphate crystals rather than urate crystals. As with gout, differentiation from an infection depends on the patient's history, the presence of pre-existing underlying diseases, and the clinical presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\", section on 'Pseudogout (\"acute CPP crystal arthritis\")'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991667\">",
"    <span class=\"h2\">",
"     Acute calcific tendinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute calcific tendinitis is caused by deposition of calcium salts around the tendons and ligaments. Patients present acutely with pain, swelling, erythema, and tenderness overlying tendons or ligaments. However, other signs of infection such as fever, lymphadenopathy, or abnormal laboratory values are absent. Radiographs demonstrate characteristic homogenous calcific densities in the area of tenderness. This process is self-limiting, and patients are managed conservatively with analgesics, rest, and splintage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991674\">",
"    <span class=\"h2\">",
"     Retained foreign bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retained foreign bodies, especially wooden splinters and thorns, can provoke an inflammatory response that can mimic an infection. Radiographs may be misleading if the foreign body is radiolucent. History is valuable in diagnosis, and removal of the offending foreign body is curative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25158?source=see_link\">",
"     \"Overview of puncture wounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991681\">",
"    <span class=\"h2\">",
"     Chemotherapeutic infiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extravasation of chemotherapeutic agents at the site of intravenous access, usually over the dorsum of the hand, may present with marked erythema and swelling. This is frequently seen with use of vesicant chemotherapeutic agents and may be mistaken for a secondary infection. The treatment of chemotherapeutic infiltration is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/13/218?source=see_link\">",
"     \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991688\">",
"    <span class=\"h2\">",
"     Pyoderma gangrenosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyoderma gangrenosum is an inflammatory skin disease commonly misdiagnosed as an infection. Pyoderma gangrenosum usually begins as small papules that are followed by central necrosis, resulting in a central ulcer with a raised border (",
"    <a class=\"graphic graphic_picture graphicRef53733 \" href=\"UTD.htm?38/17/39187\">",
"     picture 27",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52528 \" href=\"UTD.htm?7/47/7920\">",
"     picture 28",
"    </a>",
"    ). The diagnosis is often associated with underlying systemic disorders such as inflammatory bowel disease, arthritis, and lymphoproliferative disorders. The treatment of this lesion is local wound care. Surgical excision of pyoderma gangrenosum is contraindicated and may exacerbate the disease, resulting in a larger area of necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28423?source=see_link&amp;anchor=H30#H30\">",
"     \"Approach to the patient with pustular skin lesions\", section on 'Pyoderma gangrenosum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27991695\">",
"    <span class=\"h2\">",
"     Metastatic tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastatic tumors to the hand are rare and usually involve the distal phalanx; thus, they can be confused with a pulp space infection or felon (",
"    <a class=\"graphic graphic_picture graphicRef79595 \" href=\"UTD.htm?33/35/34356\">",
"     picture 29",
"    </a>",
"    ). Radiographs are useful in differentiating a tumor from infection. Primary lung tumors are the most common metastatic lesion to the hand. Other tumors that metastasize to the hand include breast, kidney, colon, thyroid, and prostate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H986789798\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early and superficial infections of the hand may respond to nonsurgical management; however, most acute infections of the hand are surgical emergencies. Prompt evaluation and proper treatment of hand infections can mean the difference between an excellent outcome and permanent disability. (See",
"      <a class=\"local\" href=\"#H27990826\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial evaluation and management of a hand injury includes a focused history and examination, laboratory evaluation, and imaging. The area of erythema should be marked to help document progression of the infection. Empiric antibiotics should be started. Elevation and heat will provide comfort for the patient. (See",
"      <a class=\"local\" href=\"#H986789529\">",
"       'Initial evaluation and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although dogs are responsible for the vast majority of animal bites, cat bites are responsible for the majority of infected bites. The rabies immunization status of the animal should be documented. (See",
"      <a class=\"local\" href=\"#H1281559770\">",
"       'Animal bites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human bites are serious injuries because of the virulence of the human oral flora. A clenched fist injury, known as a &ldquo;fight bite,&rdquo; from striking another person's mouth is often missed in the emergency department because patients are reluctant to provide an accurate history and the wound appears innocuous. This injury pattern is very likely to result in an open metacarpal head fracture and may progress to septic arthritis. (See",
"      <a class=\"local\" href=\"#H1281559777\">",
"       'Human bites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Superficial hand infections arise from the skin and subcutaneous tissue in a plane superficial to the tendons. These include cellulitis, lymphangitis, paronychia, pulp space infections, herpetic whitlow, subcutaneous abscess, and web space abscess. As a superficial hand infection progresses, it follows the path of least resistance and may involve deeper tissue planes. (See",
"      <a class=\"local\" href=\"#H27990999\">",
"       'Superficial hand infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deep hand infections are deep to the tendon sheaths and include synovial space infections, deep fascial space infections, septic arthritis, and necrotizing fasciitis. (See",
"      <a class=\"local\" href=\"#H27991348\">",
"       'Deep infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of inflammatory conditions of the hand may be wrongly diagnosed as acute infections of the hand. Some of the common mimickers of acute hand infections include gout, pseudogout, acute calcific tendinitis, retained foreign bodies, chemotherapeutic infiltration, pyoderma gangrenosum, metastatic tumor, and factitious illness. (See",
"      <a class=\"local\" href=\"#H27991646\">",
"       'Mimickers of acute hand infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/1\">",
"      Glass KD. Factors related to the resolution of treated hand infections. J Hand Surg Am 1982; 7:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/2\">",
"      Rana RS, Wu JS, Eisenberg RL. Periosteal reaction. AJR Am J Roentgenol 2009; 193:W259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/3\">",
"      Wong DC, Wansaicheong GK, Tsou IY. Ultrasonography of the hand and wrist. Singapore Med J 2009; 50:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/4\">",
"      Griego RD, Rosen T, Orengo IF, Wolf JE. Dog, cat, and human bites: a review. J Am Acad Dermatol 1995; 33:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/5\">",
"      Patzakis MJ, Wilkins J, Bassett RL. Surgical findings in clenched-fist injuries. Clin Orthop Relat Res 1987; :237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/6\">",
"      Canales FL, Newmeyer WL 3rd, Kilgore ES Jr. The treatment of felons and paronychias. Hand Clin 1989; 5:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/7\">",
"      Jebson PJ. Infections of the fingertip. Paronychias and felons. Hand Clin 1998; 14:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/8\">",
"      Hochman LG. Paronychia: more than just an abscess. Int J Dermatol 1995; 34:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/9\">",
"      Linscheid RL, Dobyns JH. Common and uncommon infections of the hand. Orthop Clin North Am 1975; 6:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/10\">",
"      Stern PJ. Selected acute infections. Instr Course Lect 1990; 39:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/11\">",
"      Watson PA, Jebson PJ. The natural history of the neglected felon. Iowa Orthop J 1996; 16:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/12\">",
"      Haedicke GJ, Grossman JA, Fisher AE. Herpetic whitlow of the digits. J Hand Surg Br 1989; 14:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/13\">",
"      Louis DS, Silva J Jr. Herpetic whitlow: herpetic infections of the digits. J Hand Surg Am 1979; 4:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/14\">",
"      Boles SD, Schmidt CC. Pyogenic flexor tenosynovitis. Hand Clin 1998; 14:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/15\">",
"      Neviaser RJ. Tenosynovitis. Hand Clin 1989; 5:525.",
"     </a>",
"    </li>",
"    <li>",
"     Kanavel A. Infections of the hand. In: A guide to the surgical treatment of acute and chronic suppurative processes in the fingers, hand, and forearm, 7th ed, Lea &amp; Febiger, Philadelphia, PA 1939.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/17\">",
"      Burkhalter WE. Deep space infections. Hand Clin 1989; 5:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/18\">",
"      Jebson PJ. Deep subfascial space infections. Hand Clin 1998; 14:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/19\">",
"      Freeland AE, Senter BS. Septic arthritis and osteomyelitis. Hand Clin 1989; 5:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/20\">",
"      Murray PM. Septic arthritis of the hand and wrist. Hand Clin 1998; 14:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/21\">",
"      Gonzalez MH. Necrotizing fasciitis and gangrene of the upper extremity. Hand Clin 1998; 14:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/22\">",
"      Dellinger EP. Severe necrotizing soft-tissue infections. Multiple disease entities requiring a common approach. JAMA 1981; 246:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/23\">",
"      Stone DR, Gorbach SL. Necrotizing fasciitis. The changing spectrum. Dermatol Clin 1997; 15:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27993/abstract/24\">",
"      Giuliano A, Lewis F Jr, Hadley K, Blaisdell FW. Bacteriology of necrotizing fasciitis. Am J Surg 1977; 134:52.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15117 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-124.240.187.81-47114297B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27993=[""].join("\n");
var outline_f27_21_27993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H986789798\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27990826\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H986789529\">",
"      INITIAL EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H986789489\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27990920\">",
"      Clinical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27990955\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27990962\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1455120627\">",
"      - Plain films",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1455120608\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281559432\">",
"      Outline the area of erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281559441\">",
"      Splinting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281559450\">",
"      Elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281559459\">",
"      Heat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281559424\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H168815709\">",
"      BITE WOUNDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281559770\">",
"      Animal bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281559777\">",
"      Human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27990999\">",
"      SUPERFICIAL HAND INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991008\">",
"      Cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1299985513\">",
"      Lymphangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991094\">",
"      Paronychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991150\">",
"      Pulp space infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991206\">",
"      Herpetic whitlow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991248\">",
"      Subcutaneous abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991298\">",
"      Web space abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27991348\">",
"      DEEP INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991357\">",
"      Synovial space infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991413\">",
"      Deep fascial space infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991462\">",
"      Septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281559541\">",
"      Necrotizing fasciitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H168815239\">",
"      MYCOBACTERIAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27991646\">",
"      MIMICKERS OF ACUTE HAND INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991653\">",
"      Gout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991660\">",
"      Pseudogout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991667\">",
"      Acute calcific tendinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991674\">",
"      Retained foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991681\">",
"      Chemotherapeutic infiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991688\">",
"      Pyoderma gangrenosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27991695\">",
"      Metastatic tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H986789798\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15117\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15117|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/55/23422\" title=\"algorithm 1\">",
"      Rx bacterial arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15117|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/21/11600\" title=\"diagnostic image 1\">",
"      Radiograph of foreign body associated with hand infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/63/9202\" title=\"diagnostic image 2\">",
"      Small fracture fragment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15117|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/4/17475\" title=\"figure 1\">",
"      Mechanism of a clenched fist injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/7/16498\" title=\"figure 2\">",
"      Surgical treatment of acute paronychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/44/28353\" title=\"figure 3\">",
"      Surgical treatment of acute eponychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/20/31049\" title=\"figure 4\">",
"      Pulp space infection Felon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/30/33255\" title=\"figure 5\">",
"      Surgical treatment of pulp space infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/14/17639\" title=\"figure 6\">",
"      Potential spaces for abscess formation on the dorsum of the hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/49/13072\" title=\"figure 7\">",
"      Web space abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/63/20470\" title=\"figure 8\">",
"      Synovial sheaths of the hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/10/29863\" title=\"figure 9\">",
"      Deep fascial spaces of the hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/0/8193\" title=\"figure 10\">",
"      Surgical treatment of thenar space abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/17/278\" title=\"figure 11\">",
"      Surgical treatment of midpalmar space abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/46/40687\" title=\"figure 12\">",
"      Surgical treatment of hypothenar space abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15117|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/4/9286\" title=\"picture 1\">",
"      Abscess associated with hand infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/54/17253\" title=\"picture 2\">",
"      Skin necrosis with MRSA infection of the hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/14/35042\" title=\"picture 3\">",
"      Marking the erythema associated with a hand infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/21/36177\" title=\"picture 4\">",
"      Hand splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/62/36833\" title=\"picture 5\">",
"      Arm sling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/24/40325\" title=\"picture 6\">",
"      Cat bite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/36/11845\" title=\"picture 7\">",
"      Fight-bite injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/44/29381\" title=\"picture 8\">",
"      Surgical treatment of human bite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/2/3107\" title=\"picture 9\">",
"      Cellulitis of the forearm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/41/36497\" title=\"picture 10\">",
"      Lymphangitis of the hand and arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/44/37571\" title=\"picture 11\">",
"      Acute paronychia lateral nail fold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/20/40260\" title=\"picture 12\">",
"      Acute eponychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/20/22851\" title=\"picture 13\">",
"      Chronic paronychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/59/32690\" title=\"picture 14\">",
"      Herpetic whitlow blister",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/30/9696\" title=\"picture 15\">",
"      Herpetic whitlow finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/31/31231\" title=\"picture 16\">",
"      Herpetic whitlow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/61/7126\" title=\"picture 17\">",
"      Digital subcutaneous abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/14/9444\" title=\"picture 18\">",
"      Postoperative subcutaneous abscess of the palm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/6/18535\" title=\"picture 19\">",
"      Surgical drainage of dorsal subcutaneous abscess of the hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/63/29685\" title=\"picture 20\">",
"      Pyogenic flexor tenosynovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/46/44772\" title=\"picture 21\">",
"      Surgical treatment of pyogenic flexor tenosynovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/28/28099\" title=\"picture 22\">",
"      Thenar space abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/41/5782\" title=\"picture 23\">",
"      Midpalmar space abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/22/8552\" title=\"picture 24\">",
"      Surgical treatment of septic arthritis of the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/5/6233\" title=\"picture 25\">",
"      Necrotizing fasciitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/22/22885\" title=\"picture 26\">",
"      Inflamed gouty tophi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/17/39187\" title=\"picture 27\">",
"      Pyoderma gangrenosum early",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/47/7920\" title=\"picture 28\">",
"      Pyoderma gangrenosum cribriform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/35/34356\" title=\"picture 29\">",
"      Metastatic cancer of the distal phalanx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15117|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 1\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/18/14637\" title=\"table 2\">",
"      Activity of antimicrobiol agents against anaerobes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/30/39404\" title=\"table 3\">",
"      Differential monoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34791?source=related_link\">",
"      Approach to Gram stain and culture results in the microbiology laboratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28423?source=related_link\">",
"      Approach to the patient with pustular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11494?source=related_link\">",
"      Blood cultures for the detection of bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21034?source=related_link\">",
"      Cutaneous manifestations of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25879?source=related_link\">",
"      Evaluation of the patient with hand pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/13/218?source=related_link\">",
"      Extravasation injury from chemotherapy and other non-neoplastic vesicants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20550?source=related_link\">",
"      Infectious tenosynovitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11942?source=related_link\">",
"      Lymphangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22707?source=related_link\">",
"      Metacarpal head fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/61/18393?source=related_link\">",
"      Overview of finger, hand, and wrist fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25158?source=related_link\">",
"      Overview of puncture wounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37846?source=related_link\">",
"      Paronychia and ingrown toenails",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=related_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=related_link\">",
"      Soft tissue infections due to human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=related_link\">",
"      Soft tissue infections following water exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=related_link\">",
"      When to use rabies prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_21_27994="Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection";
var content_f27_21_27994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27994/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27994/contributors\">",
"     Eric S Daar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27994/contributors\">",
"     Meena Lagnese, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27994/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27994/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/21/27994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/21/27994/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/21/27994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7365232\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard of care in HIV management is to completely suppress plasma HIV RNA in order to prevent the emergence of drug-resistant virus and disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This therapeutic goal becomes more difficult in the treatment-experienced HIV-infected patient with extensive drug resistance. However, advances in drug development have enabled great progress in the treatment of multidrug-resistant HIV infection. Drug discovery has led to the development of several newer agents within existing drug classes and agents within novel drug classes with alternate mechanisms of antiviral activity.",
"   </p>",
"   <p>",
"    The selection of combination antiretroviral therapy for the treatment-experienced patient is discussed here, while the initial evaluation of the treatment candidate is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9880?source=see_link\">",
"     \"Evaluation of the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detailed discussion of drug resistance testing, viral tropism, and specific mutations are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/46/3814?source=see_link\">",
"     \"Clinical trials of HIV drug resistance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365239\">",
"    <span class=\"h1\">",
"     DRUGS BY CLASS AND ABBREVIATIONS USED",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common names and abbreviations of currently available antiretroviral agents are listed by class in a separate table (",
"    <a class=\"graphic graphic_table graphicRef60927 \" href=\"UTD.htm?24/25/24989\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15956167\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of antiretroviral therapy (ART) for the treatment-naive patient generally includes the use of three active agents, which often include a &ldquo;backbone&rdquo; of two nucleoside reverse transcriptase inhibitors (NRTIs) and one additional drug class of either a protease inhibitor (PI), a nonnucleoside reverse transcriptase inhibitor (NNRTI), or an integrase strand transfer inhibitor (INSTI). The use of three fully active agents is associated with high rates of viral suppression and is the standard of care.",
"   </p>",
"   <p>",
"    However, the selection of ART for the patient with extensive drug resistance (eg, virologic failure of two or more prior regimens) is more complex since drugs from additional classes may be needed to construct a regimen that includes three fully active agents. Sometimes, partially-active drugs from four drug classes may be necessary to achieve viral suppression since three fully active agents are not available. Any change in an ART regimen in highly treatment-experienced patients should be done in consultation with an expert HIV provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365297\">",
"    <span class=\"h2\">",
"     When to expect a treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effective treatment response leads to complete virologic suppression. Although the time to suppression may vary depending upon the regimen and the patient's baseline plasma viremia, it is generally expected that undetectable levels of HIV RNA should be achieved within 24 weeks of modifying a treatment regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365304\">",
"    <span class=\"h2\">",
"     Predictors of virologic suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predictors of viral suppression in the treatment-experienced patient include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of high potency medications",
"     </li>",
"     <li>",
"      Low baseline viremia",
"     </li>",
"     <li>",
"      Baseline CD4 cell count &gt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Rapid reduction of viremia in response to treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since many of these variables are not modifiable, the use of high potency medications is critical to success. A highly potent drug for a given patient is one that is predicted to be fully active against their particular virus (as defined by treatment history and drug resistance testing). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9880?source=see_link\">",
"     \"Evaluation of the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365311\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure can include virologic, immunologic, or clinical failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link&amp;anchor=H1115408#H1115408\">",
"     \"Modifying HIV antiretroviral therapy regimens\", section on 'Immunologic failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the context of managing the treatment-experienced patient with drug-resistant virus, the focus tends to be on \"virologic failure.\" In general, virologic failure is categorized as incomplete viral suppression or viral rebound after achieving plasma HIV RNA levels below the limits of assay detection. Persistent or rebound viremia implies the emergence of drug resistance or poor medication adherence.",
"   </p>",
"   <p>",
"    The greatest concern regarding the onset of virologic failure in a patient with a history of drug resistance is the possibility of accumulating additional mutations. Drug resistance mutations can be evaluated through genotypic or phenotypic resistance testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9880?source=see_link\">",
"     \"Evaluation of the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential reasons for virologic failure include inadequate potency of the regimen, low serum drug concentrations, drug interactions and poor adherence, each of which should be considered at every clinic visit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9880?source=see_link\">",
"     \"Evaluation of the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365318\">",
"    <span class=\"h1\">",
"     THERAPEUTIC IMPLICATIONS OF DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the presence of drug resistance mutations for any particular medication will have a significant impact on the ability of that drug to suppress the patient&rsquo;s viral isolate. These mutations vary by individual drug; sometimes a particular mutation will imply lower activity of other related drugs as well. This information also needs to be combined with a thorough medication history, since resistance mutations may be archived, but not detected in resistance assays in the absence of drug pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9880?source=see_link\">",
"     \"Evaluation of the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following content addresses drug resistance by class of medications. A detailed discussion of the individual mutations associated with all available HIV drugs and general concepts in HIV drug resistance are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A brief overview of major clinical trials in highly treatment-experienced patients is also offered below; detailed discussions of these studies are found elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365325\">",
"    <span class=\"h2\">",
"     Resistance to nucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials comparing specific NRTI backgrounds in patients with history of multiple treatment failures. The choice of agent in clinical practice is mainly based on the results of drug resistance testing.",
"   </p>",
"   <p>",
"    The single most commonly seen mutation among treatment-experienced patients is the M184V mutation, which confers high-level resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extent of drug resistance to other NRTIs varies significantly based on cumulative NRTI exposure and the era in which the patient began treatment. For example, those treated in the past were typically exposed to thymidine analogs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    , with the common selection of thymidine analog mutations, such as M41L, L210W, T215Y, D67N, K70R, and",
"    <span class=\"nowrap\">",
"     K219Q/E/N",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In contrast, those starting therapy in more recent years were more likely to be exposed to non-thymidine analogs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    , where the development of drug resistance mutations is less common, typically selecting for K65R or L74V mutations. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365367\">",
"    <span class=\"h3\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all antiretroviral medications, the pattern of drug resistance will predict whether there may be no activity or partial activity of a drug against a particular viral isolate. Sometimes medications are continued with the aim of decreasing &ldquo;fitness&rdquo; of the virus, as explained below. (See",
"    <a class=\"local\" href=\"#H3365903\">",
"     'Use of NRTIs to decrease replicating virus'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15956424\">",
"    <span class=\"h4\">",
"     Thymidine analog mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with thymidine analog mutations, the particular pattern of mutations will predict which antiretroviral medications may be considered for use in future ART combinations. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      have residual activity in patients with D67N, K70R, and",
"      <span class=\"nowrap\">",
"       K219Q/E/N",
"      </span>",
"      mutations.",
"     </li>",
"     <li>",
"      In contrast, broad resistance to the NRTI drug class should be assumed among patients with M41L, L210W, and T215Y mutations. In this scenario, it is preferred to use three active agents from other drug classes, when feasible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15956440\">",
"    <span class=\"h4\">",
"     Other NRTI mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a K65R mutation, there is low level resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    , no resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , and intermediate resistance to all other NRTIs. In patients with the L74V mutation, full resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    should be expected; however, virus with this mutation has intermediate susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and remains susceptible all other NRTIs.",
"   </p>",
"   <p>",
"    In those patients with evidence of multinucleoside resistance mutations (eg, 69 insertion complex or Q151M), it is preferable to avoid the use of NRTIs; however,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    maintains some activity in patients with the Q151M complex mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3365903\">",
"    <span class=\"h4\">",
"     Use of NRTIs to decrease replicating virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a M184V mutation, high-level resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    should be expected. However, the potential benefit to continuing one of these drugs in the face of resistance is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To select for viruses with this mutation, which may improve susceptibility to other NRTIs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      To select for a less fit virus, which has decreased replication capacity compared with the original &ldquo;parent&rdquo; virus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These potential benefits may be useful in the patient with limited therapeutic options secondary to extensive multi-class drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Furthermore, continuation of FTC or 3TC does not risk additional resistance mutations and these drugs are remarkably well tolerated. Caution is need in patients with HBV coinfection. (See",
"    <a class=\"local\" href=\"#H7365595\">",
"     'Treatment strategies when treatment options are limited'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365374\">",
"    <span class=\"h2\">",
"     Resistance to nonnucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to the first generation NNRTIs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , occurs rapidly in patients with ongoing replication despite adherence to ART [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/5,14\">",
"     5,14",
"    </a>",
"    ]. The emergence of a single mutation, at either codon 181 or 103, reduces the likelihood of response to all of these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. This low genetic barrier to resistance makes NNRTIs a \"fragile\" part of any regimen. These &ldquo;signature mutations&rdquo; are frequently documented on drug resistance testing in patients with a history of prior NNRTI exposure with efavirenz or nevirapine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/5,14\">",
"     5,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, in the treatment-experienced patient with a history of NNRTI exposure, it is important to know if these signature mutations (ie, K103N) are present. In this scenario, the second generation NNRTI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    , may still be active depending on how many other accessory (additional) mutations within the NNRTI class coexist.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    is a later generation NNRTI that has only been studied in treatment-naive patients and thus should not be used in the treatment-experienced patient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    , viruses with the K103N mutation remain susceptible to rilpivirine. Among those that fail a first line regimen that includes rilpivirine frequently have the E138K mutation associated with phenotypic resistance to all available NNRTIs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=see_link&amp;anchor=H658623#H658623\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\", section on 'Efavirenz versus rilpivirine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365381\">",
"    <span class=\"h3\">",
"     Predicting the efficacy of etravirine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    (ETR) is a second generation NNRTI that has in vitro activity against many NNRTI-resistant HIV strains [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/17\">",
"     17",
"    </a>",
"    ]. Specifically, etravirine maintains activity against viral isolates with some pre-existing NNRTI mutations, such as K103N [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recent analyses have identified 17 reverse transcriptase mutations associated with a reduced response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    in those with history of virologic failure on first generation NNRTIs. Important reverse transcriptase mutations include 90I, 98G, 100I,",
"    <span class=\"nowrap\">",
"     101E/H/P,",
"    </span>",
"    106I, 138A,",
"    <span class=\"nowrap\">",
"     179D/F/T,",
"    </span>",
"    138A,",
"    <span class=\"nowrap\">",
"     181C/I/V,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     190A/S",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some researchers have proposed a weighted score for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    , which accounts for the fact that different mutations influence susceptibility more than others. The scoring system below assigns a number to different mutations, which are added up for an overall resistance score. The best virologic responses were seen when the overall score was less than or equal to 2.0, intermediate for scores of 2.5 to 3.5, and no better than the control group when the weighted overall score was greater than 3.5.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A score of 3.0 was assigned for mutations at",
"      <span class=\"nowrap\">",
"       181I/V",
"      </span>",
"     </li>",
"     <li>",
"      A score of 2.5 for 100I, 101P, 181C, and 230L",
"     </li>",
"     <li>",
"      A score of 1.5 for 106I, 179F, 138A, and 190S",
"     </li>",
"     <li>",
"      A score of 1.0 for 90I, 98G,",
"      <span class=\"nowrap\">",
"       101E/H,",
"      </span>",
"      <span class=\"nowrap\">",
"       179D/T,",
"      </span>",
"      and 190A",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365388\">",
"    <span class=\"h3\">",
"     Efficacy of etravirine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two clinical trials randomly assigned patients to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    or placebo in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    and two NRTIs with the option of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    . Both trials demonstrated that patients in the etravirine arm had significantly greater rates of viral suppression than in the placebo arm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/18\">",
"     18",
"    </a>",
"    ]. A post-hoc analysis of factors found to predict a virologic response included [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower levels of pre-treatment HIV RNA",
"     </li>",
"     <li>",
"      Higher CD4 cell counts at baseline",
"     </li>",
"     <li>",
"      Higher number of active agents in the background therapy",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"       enfuvirtide",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another post-hoc analysis has demonstrated the importance of assessing baseline NNRTI and PI resistance prior to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    in treatment-experienced patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/21\">",
"     21",
"    </a>",
"    ]. Overall response rates were as high as 93 percent among patients who had only two etravirine mutations and one darunavir mutation; in contrast, no patient with more than three etravirine mutations plus more than three darunavir mutations achieved viral suppression by 24 weeks.",
"   </p>",
"   <p>",
"    Subsequent studies have also verified the importance of incorporating additional active agents in optimizing virologic response to an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    -containing regimen, confirming the principle of using at least three active agents when constructing a new ART regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/22\">",
"     22",
"    </a>",
"    ]. One clinical trial demonstrated that the use of two or more active agents increased the likelihood of achieving HIV RNA suppression in patients with multidrug resistance by more than eightfold [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/22\">",
"     22",
"    </a>",
"    ]. Clinical trials of etravirine are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9880?source=see_link\">",
"     \"Evaluation of the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolated mutations associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    exposure, such as E138K, appear to confer some degree of cross resistance to the other NNRTIs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365395\">",
"    <span class=\"h3\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    is being considered, it is important to carefully construct a therapeutic regimen with several other active agents, such as a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PI (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    ), plus another active agent. The efficacy of etravirine will be strongly influenced by the number of etravirine mutations that are found on drug resistance testing.",
"   </p>",
"   <p>",
"    It is also important to note that there are significant drug-drug interactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    and other antiretroviral medications; for example etravirine cannot be used with the PI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no clinical data on the use of another NNRTI (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    ) after virologic failure on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    . &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365402\">",
"    <span class=\"h2\">",
"     Resistance to protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether treatment is being considered in the treatment-naive or treatment-experienced patient, all first-line PIs are given with low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    for pharmacokinetic boosting.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    is a potent cytochrome P450 inhibitor that raises the trough serum concentrations of the parent PI. This pharmacokinetic interaction can improve the drug&rsquo;s inhibition of virus by increasing the drug inhibitory quotient, which is particularly important in the patient with partial drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/25\">",
"     25",
"    </a>",
"    ]. The drug inhibitory quotient takes into account drug susceptibility of the viral isolate and drug concentrations, which are more favorable when ritonavir boosting is used. In the patient without baseline PI resistance, the emergence of PI drug resistance is rare with ritonavir boosting (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link&amp;anchor=H32#H32\">",
"     \"HIV protease inhibitors\", section on 'Pharmacokinetic boosting'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365416\">",
"    <span class=\"h3\">",
"     Predicting the efficacy of protease inhibitors in treatment-experienced patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical trials of treatment-experienced patients have included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PIs such as lopinavir [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/26\">",
"     26",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/27,28\">",
"     27,28",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/29\">",
"     29",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. From these studies, data have been derived to define genotypic and phenotypic predictors of response to each of these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/32,34\">",
"     32,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the treatment-experienced patient with multiple PI mutations at baseline, preferred options often include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    , which have activity against a wide range of drug-resistant viral isolates. As with most agents, virologic responses decline with increasing numbers of drug resistance mutations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       Darunavir",
"      </a>",
"      &mdash; In the case of darunavir, important mutations in the protease gene that negatively impact its antiviral activity include: 11I, 32I, 33F, 47V, 50V,",
"      <span class=\"nowrap\">",
"       54L/M,",
"      </span>",
"      73S, 76V, 84V and 89V. Optimal antiviral activity with darunavir is seen in patients with less than three of these mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"       Tipranavir",
"      </a>",
"      &mdash; Important mutations that negatively impact the antiviral activity of tipranavir include: 10V, 13V,",
"      <span class=\"nowrap\">",
"       20M/R/V,",
"      </span>",
"      33F, 35G, 36I, 43T, 46L, 47V",
"      <span class=\"nowrap\">",
"       54A/M/V,",
"      </span>",
"      58E, 69K, 74P,",
"      <span class=\"nowrap\">",
"       82L/T,",
"      </span>",
"      83D, and 84V. Optimal virologic response occurs among patients with less than two tipranavir-associated mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365430\">",
"    <span class=\"h3\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical cutoffs have been defined for each PI using commercially available drug resistance assays. Based upon these data, some patients may have one or more PIs predicted to be fully or partially active while other patients may have none. In the former situation, a PI can be selected based on the genotypic and phenotypic drug resistance patterns. If there is full resistance among all PI agents, it is unclear if addition of a PI will contribute any antiviral activity as part of the background regimen. In these clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    , the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    increased rates of viral suppression, again supporting the need for two or more fully active agents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With all PIs, consideration must also be given to drug-drug interactions and unique side-effect profiles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365437\">",
"    <span class=\"h2\">",
"     Resistance to fusion inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     Enfuvirtide",
"    </a>",
"    is a 36 amino acid peptide that binds to the envelope glycoprotein 41 (gp41) of HIV, which is critical for viral fusion to the CD4+ T cell. When administered as a subcutaneous injection twice daily, enfuvirtide significantly reduces viral load in patients with multidrug-resistant HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, single mutations do confer high level resistance and lead to virologic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365444\">",
"    <span class=\"h3\">",
"     Efficacy of enfuvirtide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     Enfuvirtide",
"    </a>",
"    is an important component of ART in patients with multidrug resistance. In two clinical trials (TORO 1 and TORO 2), patients who were randomly assigned to receive enfuvirtide plus optimized background therapy (based on drug resistance testing) had a significantly higher viral load decline (0.8 to 1.0 log difference in HIV RNA) and a significantly higher CD4 cell count increase compared with those who received placebo plus optimized background therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. These and other data in patients with multidrug-resistant virus demonstrate the utility of enfuvirtide as an integral component of a new ART regimen. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365451\">",
"    <span class=\"h3\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon data from the pivotal TORO trials, those who are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    -na&iuml;ve are likely to have virus that is susceptible to the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In contrast, since resistance appears to emerge fairly quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], those with a history of viremia on this drug are likely to have selected for enfuvirtide-resistant virus. One disadvantage of enfuvirtide is the need for subcutaneous injections. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     \"Enfuvirtide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365458\">",
"    <span class=\"h2\">",
"     Resistance to CCR5 antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     Maraviroc",
"    </a>",
"    is the only currently approved drug in this class. This drug is indicated for treatment-na&iuml;ve and treatment-experienced patients who do not have detectable CXCR4-using virus, as determined by a tropism assay.",
"   </p>",
"   <p>",
"    CXCR4-using virus is fairly common in treatment-experienced patients and in those with lower T cell counts (eg, &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. In one study, a substantial number of patients experiencing virologic failure on a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    -containing regimen had detectable CXCR4-using virus with a small number having true maraviroc drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/45\">",
"     45",
"    </a>",
"    ]. Improvements in the sensitivity of tropism testing have improved the identification of patients who will not benefit from a CCR5 antagonist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365465\">",
"    <span class=\"h3\">",
"     Efficacy of maraviroc in treatment-experienced patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two clinical trials (MOTIVATE 1 and 2), treatment-experienced patients without detectable CXCR4-using virus who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    with an optimized background regimen had significantly greater reductions in plasma HIV RNA than patients assigned to the optimized background therapy alone arm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/46\">",
"     46",
"    </a>",
"    ]. In contrast, little antiviral activity has been seen with maraviroc among patients who had detectable CXCR4-using virus at screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/47\">",
"     47",
"    </a>",
"    ]. Thus, maraviroc use should be restricted to those without CXCR4-tropic virus, as determined by tropism testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consistent with other trials, the \"first use\" of other agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    ) in the selected optimized background ART regimen in the MOTIVATE trials led to more favorable virologic outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365472\">",
"    <span class=\"h3\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without detectable CXCR4-using viruses are candidates for treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    along with other active agents. Tropism testing should be performed prior to initiation of maraviroc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365479\">",
"    <span class=\"h2\">",
"     Resistance to integrase strand transfer inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    is the only currently approved stand-alone drug that inhibits proviral integration and is approved for treatment-experienced patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/48\">",
"     48",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Elvitegravir is a recently approved drug from this class but is currently only available as part of a fixed-dose combination with a new pharmacologic booster, cobicistat,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    DF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    . This new combination pill is approved for those initiating antiretroviral therapy for the first time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signature mutations in the integrase gene associated with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    include",
"    <span class=\"nowrap\">",
"     Q148H/K/R,",
"    </span>",
"    <span class=\"nowrap\">",
"     Y143R/H/C",
"    </span>",
"    and N155H. Data from treatment trials with raltegravir showed that 67 percent of those experiencing protocol-defined virologic failure had at least one of these common mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/51\">",
"     51",
"    </a>",
"    ]. Although there is likely to be considerable cross-resistance between raltegravir and elvitegravir, there is no cross-resistance between these drugs and drugs from other classes. However, the use of these drugs in a combination that does not include other active drugs is associated with the rapid loss of activity due to its low genetic barrier to resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365486\">",
"    <span class=\"h3\">",
"     Efficacy data supporting integrase strand transfer inhibitors for treatment-experienced patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two double-blind placebo-controlled trials (BENCHMRK-1 and BENCHMRK-2) have demonstrated that patients with triple class experience (ie, NRTI, NNRTI, and PI) randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    plus optimized background therapy had higher rates of viral suppression at 48 weeks than patients assigned to optimized background alone (62 versus 33 percent, respectively) with a significantly higher increase in CD4 T cell counts (109 versus 45",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/52\">",
"     52",
"    </a>",
"    ]. Subgroup analyses demonstrated optimal HIV RNA declines among those receiving at least two other active drugs in the optimized background regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     \"Raltegravir: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    has also been evaluated as a replacement for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    in several studies of patients with multidrug-resistant HIV who were virologically suppressed on an enfuvirtide-containing regimen. One clinical trial of 170 patients demonstrated similar virologic suppression when patients either continued enfuvirtide or were switched to raltegravir [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/53\">",
"     53",
"    </a>",
"    ]. The potential advantage of such a strategy would be the elimination of twice-daily injections associated with enfuvirtide administration.",
"   </p>",
"   <p>",
"    While the fixed-dose combination of elvitegravir with cobicistat,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    DF, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    is not yet approved for treatment-experienced patients, it is anticipated that elvitegravir will be FDA-approved as a stand-alone drug for this patient population. In such patients, elvitegravir has been shown to be noninferior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    with regards to viral suppression when used in combination with an optimized background regimen that includes a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link&amp;anchor=H4926535#H4926535\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\", section on 'Treatment-experienced patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365493\">",
"    <span class=\"h3\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    is a therapeutic option for treatment-na&iuml;ve and treatment-experienced patients. Due to its low genetic barrier to resistance, raltegravir should ideally be used in combination with at least two fully active agents to decrease the risk of rapid emergence of drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365500\">",
"    <span class=\"h1\">",
"     SELECTING A REGIMEN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3089092\">",
"    <span class=\"h2\">",
"     Historical perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral suppression was strongly linked to a lower risk of disease progression in the first clinical trials that used protease inhibitors (PIs) for HIV treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/55\">",
"     55",
"    </a>",
"    ]. The last HIV treatment trial that used clinical endpoints (eg, progression to AIDS or death) was published in 1997; this randomized trial compared dual nucleoside reverse transcriptase inhibitors (NRTIs) versus two NRTIs plus a PI and found a 50 percent reduction in morbidity and mortality in the triple therapy arm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11286?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This and other early clinical treatment trials among treatment-na&iuml;ve and treatment-experienced patients have demonstrated that viral suppression is associated with a lower risk of clinical progression and death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. The use of three fully-active drugs has been the optimal goal of therapy ever since and the achievement of viral suppression has been used as the benchmark of therapeutic efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. Post-hoc analyses from multiple contemporary trials among treatment-experienced patients support this treatment principle by demonstrating that the higher the number of active drugs in a ART regimen, the greater the chance of viral suppression in patients with multidrug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/20-22,29,31,33,37,38,51\">",
"     20-22,29,31,33,37,38,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11286?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)\", section on 'Comparisons of dual and triple therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365509\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently many potential drugs to consider as part of a regimen for treatment-experienced patients with drug-resistant virus. In light of the diversity of patient medication histories, drug resistance profiles, and treatment options, there will never be studies to formally compare all potential regimens in this patient population.",
"   </p>",
"   <p>",
"    However, the guiding principle that has emerged from various trials is that two, and ideally three, fully active agents representing at least two different classes should be included in any new ART regimen. When possible, we recommend three fully active drugs from three different classes of antiretroviral medications to increase the likelihood of attaining viral suppression and to decrease the risk of drug resistance. Genotypic and phenotypic drug resistance testing and a thorough medical history help to determine which drugs may be fully active.",
"   </p>",
"   <p>",
"    These principles were well illustrated in a non-comparative trial (TRIO), which evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"      darunavir",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    among 103 HIV-infected patients with multidrug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/59\">",
"     59",
"    </a>",
"    ]. The patients were heavily treatment-experienced with three or more PI mutations and three or more NRTI mutations at baseline. However, all were na&iuml;ve to raltegravir, etravirine, and",
"    <span class=\"nowrap\">",
"     darunavir/ritonavir",
"    </span>",
"    with predicted susceptibility based on drug resistance testing to the NNRTI and PI. In addition, 87 percent of the patients were also given optimized background therapy (based on drug resistance testing) including either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    or NRTIs. At 24 weeks, 90 percent of the patients had achieved virologic suppression. Of the 100 patients who participated in extended follow-up, 88 percent maintained viral suppression with a median increase of 150 CD4+ T",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/60\">",
"     60",
"    </a>",
"    ]. No major toxicity was reported.",
"   </p>",
"   <p>",
"    Although this was a small noncomparative trial, the rates of viral suppression were high and comparable to those seen even among treatment-naive patients. Another trial is in progress (ie, ACTG 5241) to determine if NRTI background therapy is necessary to achieve viral suppression in patients with three-class drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17672?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\", section on 'Darunavir versus lopinavir (ARTEMIS)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\", section on 'Treatment-naive patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Considerations for selection of individual antiretroviral medications for the treatment-experienced patient are summarized below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365516\">",
"    <span class=\"h2\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PI, if there is predicted susceptibility to one of these agents based upon drug resistance testing. In patients with a history of drug resistance to multiple PIs, treatment options are often limited to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H7365402\">",
"     'Resistance to protease inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The efficacy of these agents is affected by the number of preexisting mutations. For optimum results,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    may be considered in patients with less than two tipranavir-associated mutations;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    can be considered in patients with less than three darunavir-associated mutations. If both options are feasible, we prefer darunavir rather than tipranavir, since the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    dosage is lower with darunavir than with tipranavir (100 mg twice daily versus 200 mg twice daily, respectively). Ritonavir can lead to hyperlipidemia and gastrointestinal upset at higher doses. Darunavir is also associated with fewer drug-drug interactions than tipranavir and is generally well tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Twice-daily dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    is recommended for treatment-experienced patients with multidrug-resistant virus; however, if there are no darunavir-resistant mutations the drug can be given once daily at a dose of 800 mg with 100 mg ritonavir [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend the use of two PIs within a combination regimen, because this approach is associated with substantial toxicity, complex drug-drug interactions, and no clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/62\">",
"     62",
"    </a>",
"    ]. &nbsp;This statement does not apply to the use of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    for pharmacokinetic boosting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365523\">",
"    <span class=\"h2\">",
"     Nucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with extensive NRTI drug resistance, one of two alternative treatment strategies can be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NRTIs can be omitted entirely from an ART regimen in the patient with extensive NRTI drug resistance who has the option of three or more fully active drugs from other drug classes.",
"     </li>",
"     <li>",
"      In patients with limited treatment options (ie, two or less fully active available agents), one alternative is to combine potentially partially active agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      along with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      . Use of either lamivudine or emtricitabine leads to continued selection for the M184V mutation, which confers high level resistance to both of these drugs; however, viral isolates with the M184V mutation are hypersusceptible to tenofovir. In addition, HIV isolates with the M184V mutation have a lower replicative capacity than the parent strain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/11\">",
"       11",
"      </a>",
"      ]. This strategy can be considered to enhance the chances of viral suppression or to delay disease progression among those in whom viral suppression cannot be achieved. (See",
"      <a class=\"local\" href=\"#H7365595\">",
"       'Treatment strategies when treatment options are limited'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365530\">",
"    <span class=\"h2\">",
"     Nonnucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a history of virologic failure on first generation NNRTIs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    may be an efficacious agent.",
"   </p>",
"   <p>",
"    However, in patients with significant NRTI resistance, optimal background ART must be carefully selected when using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    . Preferred treatment strategies include combining etravirine with at least two other fully active drugs, one of which usually includes a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PI. Clinical trial data on the use of etravirine is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not recommend the use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    if results of drug resistance testing demonstrate likely resistance to etravirine (see",
"    <a class=\"local\" href=\"#H7365374\">",
"     'Resistance to nonnucleoside reverse transcriptase inhibitors'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365537\">",
"    <span class=\"h2\">",
"     Fusion inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    in patients who have not been exposed to this medication in the past and who require this drug to complete an active three-drug regimen. Enfuvirtide can be safely considered to be a fully active agent among those who are enfuvirtide-na&iuml;ve.",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    is difficult to administer for long periods of time due to the need for twice-daily injections, which often lead to local cutaneous reactions. In patients with viral suppression who are having difficulty with injection site reactions, we prefer to switch enfuvirtide to a regimen containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , if the patient has not been previously exposed to this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/53,63\">",
"     53,63",
"    </a>",
"    ]. Switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    is another option, but limited by the absence of data and the inability to assess for plasma HIV tropism in those with suppressed virus. (See",
"    <a class=\"local\" href=\"#H7365544\">",
"     'CCR5 receptor antagonists'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365544\">",
"    <span class=\"h2\">",
"     CCR5 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    in patients without detectable CXCR4-using virus in combination with preferably two other fully active drugs from other classes. Tropism testing is required prior to administration since there is no other way to know whether this will be an active agent for any given patient. Tropism testing should only be performed if you anticipate using this drug as part of the next regimen; a patient who does not have CXCR4-using viruses now may still develop them in the future if they are not maintained on a fully suppressive drug regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of HIV drug resistance testing assays\", section on 'Tropism assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365551\">",
"    <span class=\"h2\">",
"     Integrase strand transfer inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    is a well-tolerated, potent agent that can be used in patients with extensive resistance to drugs in other classes; optimal efficacy is achieved when raltegravir is used in combination with at least one and preferably two other fully active drugs.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    is very well tolerated and is lipid neutral; thus it is an attractive \"switch\" option in patients who are taking twice-daily injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    or in those patients who have elevated triglycerides or cholesterol. Although switching from enfuvirtide appears to be well tolerated in patients with limited treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/53\">",
"     53",
"    </a>",
"    ], switching from a PI-based regimen may increase the rates of viral failure if the other drugs included in the regimen are not highly active [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365595\">",
"    <span class=\"h1\">",
"     TREATMENT STRATEGIES WHEN TREATMENT OPTIONS ARE LIMITED",
"    </span>",
"    &nbsp;&mdash;&nbsp;If full suppression is unlikely to be achieved with currently available medications, serious considerations must be given to alternative strategies in order to avoid adding one new drug to a failing regimen, where the emergence of resistance is likely. Such patients should be managed with the assistance of a highly-experienced HIV provider.",
"   </p>",
"   <p>",
"    One option includes continuing the same drug regimen until new therapies may be available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/66\">",
"     66",
"    </a>",
"    ]. Treatment discontinuation is not recommended since this approach is associated with clinical progression, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6189949\">",
"    <span class=\"h2\">",
"     Incomplete viral suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with incomplete viral suppression due to multi-drug resistance usually have lower levels of viremia than their pretreatment baseline. HIV may be constrained in its ability to become both highly resistant and highly fit; this may contribute to the continued partial suppression of plasma HIV RNA levels, which is observed in some patients with drug-resistant virus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/67\">",
"     67",
"    </a>",
"    ]. Partially suppressive regimens preserve CD4 cell counts and maintain clinical stability, while awaiting new therapeutic options [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/11,68\">",
"     11,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This is particularly true of combination ART that includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , which lead to HIV variants with the M184V mutation. When NRTI drug pressure is removed and drug resistant viruses with M184V are replaced by wild-type virus, replication capacity increases and higher levels of viremia are observed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Thus, one approach in the patient with multidrug resistance is to continue therapy with NRTIs, or with NRTIs plus a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PI, in order to maintain a less fit virus. Such an approach may lower the risk of clinical progression, as compared to complete treatment cessation. (See",
"    <a class=\"local\" href=\"#H6189971\">",
"     'Treatment discontinuation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are currently little data to suggest that continued use of NNRTIs, fusion inhibitors, INSTIs, or CCR5 antagonists will have any residual activity when drug resistance to these agents is present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/11,69\">",
"     11,69",
"    </a>",
"    ]. In addition, the continued use of any of these agents may result in increasing numbers of mutations, which can limit the clinical utility of later generation drugs within the same class [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/11,69\">",
"     11,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6189971\">",
"    <span class=\"h2\">",
"     Treatment discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach in this setting is to stop therapy and monitor the patient off antiretroviral treatment. While this would not result in the accumulation of additional drug resistance mutations, several studies have shown that this approach can be associated with increased risk of clinical progression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/11,68,70,71\">",
"     11,68,70,71",
"    </a>",
"    ]. Although less than ideal, we prefer the continuation of therapy with partially active drugs versus treatment discontinuation to avoid rapid clinical deterioration, particularly amongst those with a history of having a low CD4 cell count in the past.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365602\">",
"    <span class=\"h1\">",
"     STRATEGIES OF UNPROVEN BENEFIT OR HARM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365610\">",
"    <span class=\"h2\">",
"     Structured treatment interruption and the importance of archived resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have evaluated whether treatment interruption may lead to reversion of drug resistance mutations and better virologic efficacy when ART is re-introduced [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/70\">",
"     70",
"    </a>",
"    ]. Discontinuation of partially effective therapy is associated with immunologic decline and increasing levels of HIV RNA compared with patients who continue taking ART. Although clinical trial data demonstrate that drug resistance mutations may revert, there is no treatment benefit and there is an increased risk of clinical progression during the treatment interruption [",
"    <a class=\"abstract\" href=\"UTD.htm?27/21/27994/abstract/70\">",
"     70",
"    </a>",
"    ]. Thus, we do not recommend this strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7365617\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The standard of care in HIV management is to completely suppress plasma HIV RNA in order to prevent the emergence of drug-resistant virus and disease progression. Drug resistance testing can identify which drugs are fully or partially active. (See",
"      <a class=\"local\" href=\"#H7365232\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The selection of antiretroviral therapy (ART) for the patient with extensive drug resistance (eg, virologic failure of two or more prior regimens) is complex. Any change in an ART regimen in highly treatment-experienced patients should be done in consultation with an expert HIV provider. (See",
"      <a class=\"local\" href=\"#H15956167\">",
"       'General approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the time to viral suppression may vary depending upon the regimen and the patient's baseline plasma viremia, it is generally expected that undetectable levels of HIV RNA should be achieved within 24 weeks of modifying a treatment regimen. (See",
"      <a class=\"local\" href=\"#H7365297\">",
"       'When to expect a treatment response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the presence of drug resistance mutations for any particular drug will have a significant negative impact on the ability of that medication to suppress the patient&rsquo;s viral isolate. Information from drug resistance testing also needs to be combined with a thorough medication history, since resistance mutations may be archived, but not detected. (See",
"      <a class=\"local\" href=\"#H7365318\">",
"       'Therapeutic implications of drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend three fully active drugs for inclusion in combination therapy in the HIV-infected patient with multidrug resistance, whenever possible (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This strategy increases the likelihood of attaining viral suppression and decreases the risk of further drug resistance. (See",
"      <a class=\"local\" href=\"#H7365500\">",
"       'Selecting a regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a history of drug resistance to multiple PIs, treatment options are often limited to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      or ritonavir-boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"       tipranavir",
"      </a>",
"      , which have a high genetic barrier to resistance and broad activity against a wide range of drug-resistant viral isolates. (See",
"      <a class=\"local\" href=\"#H7365402\">",
"       'Resistance to protease inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a history of virologic failure on first generation nonnucleoside reverse transcriptase inhibitors (NNRTIs),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"       etravirine",
"      </a>",
"      may be an efficacious agent. In patients who also have significant NRTI resistance, optimal background ART must be carefully selected. For patients who are going to start etravirine, we recommend the addition of at least two other fully active agents (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7365530\">",
"       'Nonnucleoside reverse transcriptase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"       Enfuvirtide",
"      </a>",
"      is an effective component in combination ART among patients who have not been exposed to this medication in the past. (See",
"      <a class=\"local\" href=\"#H7365537\">",
"       'Fusion inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients without detectable CXCR4-using viruses are candidates for treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"       maraviroc",
"      </a>",
"      , a CCR5 antagonist, along with other active agents. Viral tropism testing should be performed prior to initiation of maraviroc. (See",
"      <a class=\"local\" href=\"#H7365458\">",
"       'Resistance to CCR5 antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are going to start",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      , we recommend the addition of two fully active agents from different drug classes (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This strategy is needed because of raltegravir&rsquo;s low genetic barrier to resistance. (See",
"      <a class=\"local\" href=\"#H7365479\">",
"       'Resistance to integrase strand transfer inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with extensive NRTI resistance, and susceptibility to three or more fully active medications from other drug classes, we suggest NOT using an NRTI. Instead, three active drugs from other classes should be prescribed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7365523\">",
"       'Nucleoside reverse transcriptase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients for who there are no suppressive regimens, we recommend a partially suppressive regimen rather than discontinuing ART (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7365602\">",
"       'Strategies of unproven benefit or harm'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/1\">",
"      Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on March 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/3\">",
"      Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/4\">",
"      Yamashita TE, Phair JP, Mu&ntilde;oz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/5\">",
"      Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/6\">",
"      Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/7\">",
"      MacManus S, Yates PJ, Elston RC, et al. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004; 18:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/8\">",
"      Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 2004; 292:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/9\">",
"      Whitcomb JM, Parkin NT, Chappey C, et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/10\">",
"      Johnson VA, Brun-V&eacute;zinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/11\">",
"      Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/12\">",
"      Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 41:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/13\">",
"      Eron JJ Jr, Bartlett JA, Santana JL, et al. Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004; 37:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/14\">",
"      Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/15\">",
"      Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/16\">",
"      Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/17\">",
"      Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79:12773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/18\">",
"      Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/19\">",
"      Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010; 24:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/20\">",
"      Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23:2289.",
"     </a>",
"    </li>",
"    <li>",
"     Haubrich R, Schapiro J, Vigerhoets J, et al. Combined darunavir and etravirine resistance analysis of the pooled DUET trials: when can we spare the other new classes? XVII International AIDS Conference, August 3-8, 2008, Mexico City. Abstract #Tupe0048.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/22\">",
"      Marcelin AG, Flandre P, Descamps D, et al. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother 2010; 54:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/23\">",
"      Asahchop EL, Oliveira M, Wainberg MA, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother 2011; 55:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/24\">",
"      Tambuyzer L, Nijs S, Daems B, et al. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr 2011; 58:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/25\">",
"      Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002; 46:3907.",
"     </a>",
"    </li>",
"    <li>",
"     DeJesus E, LaMarca A, Sension M, et al. The Context Study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virologic failure (24 week results). 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, February 9-14, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/27\">",
"      Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/28\">",
"      Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/29\">",
"      Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/30\">",
"      Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/31\">",
"      Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/32\">",
"      Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007; 46:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/33\">",
"      Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/34\">",
"      Naeger LK, Struble KA. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS 2006; 20:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/35\">",
"      De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/36\">",
"      Naeger LK, Struble KA. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 2007; 21:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/37\">",
"      Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/38\">",
"      Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/39\">",
"      Lu J, Deeks SG, Hoh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 2006; 43:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/40\">",
"      Poveda E, Rod&eacute;s B, Lebel-Binay S, et al. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol 2005; 34:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/41\">",
"      Daar ES, Kesler KL, Petropoulos CJ, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/42\">",
"      Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/43\">",
"      Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006; 194:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/44\">",
"      Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44:591.",
"     </a>",
"    </li>",
"    <li>",
"     Jubb B, Lewis M, Simpson P, et al. CCR5-tropic resistance to maraviroc is uncommon even among patients on functional maraviroc monotherapy or with ongoing low-level replication. Presented as an abstract at 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 8-11 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/46\">",
"      Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/47\">",
"      Saag M, Goodrich J, F&auml;tkenheuer G, et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009; 199:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/48\">",
"      Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/49\">",
"      Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/50\">",
"      DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/51\">",
"      Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/52\">",
"      Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/53\">",
"      De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009; 49:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/54\">",
"      Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012; 12:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/55\">",
"      Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/56\">",
"      Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996; 335:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/57\">",
"      Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997; 126:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/58\">",
"      Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/59\">",
"      Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/60\">",
"      Fagard C, Colin C, Charpentier C, et al. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr 2012; 59:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/61\">",
"      Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011; 25:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/62\">",
"      F&auml;tkenheuer G, Hoetelmans RM, Hunn N, et al. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients. AIDS 1999; 13:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/63\">",
"      Towner W, Klein D, Kerrigan HL, et al. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr 2009; 51:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/64\">",
"      Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/65\">",
"      Mart&iacute;nez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/66\">",
"      Hatano H, Hunt P, Weidler J, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis 2006; 43:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/67\">",
"      Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002; 76:11104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/68\">",
"      Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998; 351:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/69\">",
"      Deeks SG, Lu J, Hoh R, et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007; 195:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/70\">",
"      Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/21/27994/abstract/71\">",
"      Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13979 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-6250843016-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27994=[""].join("\n");
var outline_f27_21_27994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7365617\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7365232\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7365239\">",
"      DRUGS BY CLASS AND ABBREVIATIONS USED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15956167\">",
"      GENERAL APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365297\">",
"      When to expect a treatment response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365304\">",
"      Predictors of virologic suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365311\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7365318\">",
"      THERAPEUTIC IMPLICATIONS OF DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365325\">",
"      Resistance to nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365367\">",
"      - Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15956424\">",
"      Thymidine analog mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15956440\">",
"      Other NRTI mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3365903\">",
"      Use of NRTIs to decrease replicating virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365374\">",
"      Resistance to nonnucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365381\">",
"      - Predicting the efficacy of etravirine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365388\">",
"      - Efficacy of etravirine therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365395\">",
"      - Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365402\">",
"      Resistance to protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365416\">",
"      - Predicting the efficacy of protease inhibitors in treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365430\">",
"      - Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365437\">",
"      Resistance to fusion inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365444\">",
"      - Efficacy of enfuvirtide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365451\">",
"      - Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365458\">",
"      Resistance to CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365465\">",
"      - Efficacy of maraviroc in treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365472\">",
"      - Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365479\">",
"      Resistance to integrase strand transfer inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365486\">",
"      - Efficacy data supporting integrase strand transfer inhibitors for treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7365493\">",
"      - Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7365500\">",
"      SELECTING A REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3089092\">",
"      Historical perspective",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365509\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365516\">",
"      Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365523\">",
"      Nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365530\">",
"      Nonnucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365537\">",
"      Fusion inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365544\">",
"      CCR5 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365551\">",
"      Integrase strand transfer inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7365595\">",
"      TREATMENT STRATEGIES WHEN TREATMENT OPTIONS ARE LIMITED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6189949\">",
"      Incomplete viral suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6189971\">",
"      Treatment discontinuation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7365602\">",
"      STRATEGIES OF UNPROVEN BENEFIT OR HARM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7365610\">",
"      Structured treatment interruption and the importance of archived resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7365617\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13979\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13979|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/25/24989\" title=\"table 1\">",
"      Antiretroviral drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11286?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17672?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/46/3814?source=related_link\">",
"      Clinical trials of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=related_link\">",
"      Enfuvirtide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9880?source=related_link\">",
"      Evaluation of the treatment-experienced patient with drug-resistant HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=related_link\">",
"      Overview of HIV drug resistance testing assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=related_link\">",
"      Raltegravir: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_21_27995="Pseudoporphyria and PCT differential";
var content_f27_21_27995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of pseudoporphyria and porphyria cutanea tarda",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pseudoporphyria",
"       </td>",
"       <td class=\"subtitle1\">",
"        PCT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Drugs",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        Naproxen",
"        <br/>",
"        Voriconazole",
"        <br/>",
"        Tetracycline",
"        <br/>",
"        Furosemide",
"        <br/>",
"        Imatinib",
"       </td>",
"       <td class=\"centered\">",
"        Alcohol",
"        <br/>",
"        Estrogens",
"        <br/>",
"        Iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Sclerodermoid changes",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Hypertrichosis",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Hyperpigmentation",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Porphyrin abnormalities",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27995=[""].join("\n");
var outline_f27_21_27995=null;
var title_f27_21_27996="Causes hypocalcemia children";
var content_f27_21_27996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of hypocalcemia in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Loss of calcium from the circulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperphosphatemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alkalosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravascular complexing with citrate, lactate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypoparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Impaired synthesis or secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Genetic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        DiGeorge Syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        HDR Syndrome (Hypoparathyroidism, deafness, renal anomaly)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sanjad-Sakati syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mitochondrial disorders (eg, MELAS Syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Defect of the calcium sensing receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Autoimmune",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Autoimmune polyglandular syndrome type 1 (APS1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Thyroid or parathyroid gland surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Infilitration of parathyroid gland",
"(eg, iron overload)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Infection (eg, gram-negative sepsis, HIV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pseudohypoparathyroidism (End organ resistance)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Type 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Type 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypovitaminosis D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Impaired synthesis or intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Insufficient dietary intake and/or sun exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Decreased gastrointestinal absorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin D resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypomagnesemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hungry bone syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoride poisoning",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27996=[""].join("\n");
var outline_f27_21_27996=null;
var title_f27_21_27997="Flow function relationship";
var content_f27_21_27997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flow-function relationship in hibernating and stunned myocardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 276px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The red line demonstrates the relationship between the amount of myocardial blood flow and left ventricular systolic function (flow-function relationship). When myocardium is operating below this line, function is disproportionately depressed relative to flow and when it is above the line, function exceeds blood flow and ischemia is likely to result. Chronically hypoperfused myocardium, resulting from an epicardial stenosis that restricts basal coronary flow, produces hibernation (H). In comparison, stunning (S), resulting from repetitive bouts of ischemia, occurs when the stenosis severely limits flow reserve but not basal coronary flow. Small variations in blood flow may result in a change in myocardial state, between H and S, without any appreciable change in systolic function. Following inotropic stimulation, myocardium operating at both H and S will increase systolic function without a substantial change in blood flow (A and B, respectively). As a result, the two situations cannot be reliably distinguished by stress echocardiography.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Redwood SR, Ferrari R, Marber MS. Heart 1998; 80:218.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27997=[""].join("\n");
var outline_f27_21_27997=null;
var title_f27_21_27998="Gram stain lung 1B answer";
var content_f27_21_27998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Legionella micdadei",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Modified acid-fast stain of lung biopsy (x1000) shows small reddish coccobacilli; Legionella micdadei grew on culture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27998=[""].join("\n");
var outline_f27_21_27998=null;
var title_f27_21_27999="Laryngomalacia";
var content_f27_21_27999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Laryngomalacia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Flexible laryngoscopy of laryngomalacia during inspiration. Note collapse of the epiglottis. Panel B: Flexible laryngoscopy of laryngomalacia during expiration. Note the omega-shaped epiglottis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_21_27999=[""].join("\n");
var outline_f27_21_27999=null;
